beta

GERN

Geron Corporation

Gern

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 03-06-2019 after market close 11-01-2018 after market close 07-31-2018 after market close 05-10-2018 03-16-2018 after market close 11-01-2017 after market close 08-09-2017 after market close 05-09-2017 after market close
Actual EPS -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.03 -0.04 -0.04 -0.05 -0.04 -0.04 -0.05
Consensus EPS -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.04 -0.04 -0.05 -0.05 -0.05
Estimated EPS -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.05 -0.04 -0.04 -0.05 -0.05 -0.05
Number of Estimates 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2
EPS Surprise $0.02 -$0.01 $0.01 $0.01

Stats

Summary

Geron Corp is a biopharmaceutical company. It supports the clinical stage development of a telomerase inhibitor, imetelstat.

Market Cap: 320 Million

Primary Exchange: Nasdaq Global Select

Website: http://www.geron.com

Shares Outstanding: 159 Million

Float: 154 Million

Dividend: 0.0 (0.0%)

Beta: 2.547626

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 32.8 Million

Ethical Flags

Animal testing

Longest drawdown: 1081 trading days

From: 2013-12-05 To: 2018-03-23

Lowest Point:

Geron Corporation (GERN) CEO John Scarlett on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-16 09:30:07:000

Geron Corporation. (GERN) Q1 2019 Results Earnings Conference Call May 16, 2019, 09:00 AM ET Company Participants Suzanne Messere - Investor Relations John Scarlett - Chairman and CEO Olivia Bloom - Chief Financial Officer Andrew Grethlein - Chief Operating Officer Aleksandra… read more...

Geron Corporation (GERN) CEO John Scarlett on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-16 09:30:07:000

Geron Corporation. (GERN) Q1 2019 Results Earnings Conference Call May 16, 2019, 09:00 AM ET Company Participants Suzanne Messere - Investor Relations John Scarlett - Chairman and CEO Olivia Bloom - Chief Financial Officer Andrew Grethlein - Chief Operating Officer Aleksandra… read more...

Geron Corporation (GERN) CEO John Scarlett on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-16 09:30:07:000

Geron Corporation. (GERN) Q1 2019 Results Earnings Conference Call May 16, 2019, 09:00 AM ET Company Participants Suzanne Messere - Investor Relations John Scarlett - Chairman and CEO Olivia Bloom - Chief Financial Officer Andrew Grethlein - Chief Operating Officer Aleksandra… read more...

Geron down 6% on extended timeline for imetelstat in myelofibrosis

via: SeekingAlpha at 2019-05-16 08:36:07:000

Geron ( GERN -5.9% ) slips on below-average volume in apparent response to its revised development timeline for imetelstat in myelofibrosis. More news on: Geron Corporation, Healthcare stocks news, Stocks on the move, Read more … read more...

Geron down 6% on extended timeline for imetelstat in myelofibrosis

via: SeekingAlpha at 2019-05-16 08:36:07:000

Geron ( GERN -5.9% ) slips on below-average volume in apparent response to its revised development timeline for imetelstat in myelofibrosis. More news on: Geron Corporation, Healthcare stocks news, Stocks on the move, Read more … read more...

Geron down 6% on extended timeline for imetelstat in myelofibrosis

via: SeekingAlpha at 2019-05-16 08:36:07:000

Geron ( GERN -5.9% ) slips on below-average volume in apparent response to its revised development timeline for imetelstat in myelofibrosis. More news on: Geron Corporation, Healthcare stocks news, Stocks on the move, Read more … read more...

Geron: A Very Long Wait For A Very Long Shot

via: SeekingAlpha at 2019-05-03 05:57:55:000

After Geron's ( GERN ) stock price experienced a meteoric rise and equally spectacular fall in the second half of 2018, it appears as though the stock might finally be about to stabilize. After reaching an intra-day high of $6.99 (market cap of $1.29B) on 09/13/18, Johnson & Johnson-owned … read more...

Geron: A Very Long Wait For A Very Long Shot

via: SeekingAlpha at 2019-05-03 05:57:55:000

After Geron's ( GERN ) stock price experienced a meteoric rise and equally spectacular fall in the second half of 2018, it appears as though the stock might finally be about to stabilize. After reaching an intra-day high of $6.99 (market cap of $1.29B) on 09/13/18, Johnson & Johnson-owned … read more...

Geron: A Very Long Wait For A Very Long Shot

via: SeekingAlpha at 2019-05-03 05:57:55:000

After Geron's ( GERN ) stock price experienced a meteoric rise and equally spectacular fall in the second half of 2018, it appears as though the stock might finally be about to stabilize. After reaching an intra-day high of $6.99 (market cap of $1.29B) on 09/13/18, Johnson & Johnson-owned … read more...

Geron: A Very Long Wait For A Very Long Shot

via: SeekingAlpha at 2019-05-03 05:57:55:000

After Geron's ( GERN ) stock price experienced a meteoric rise and equally spectacular fall in the second half of 2018, it appears as though the stock might finally be about to stabilize. After reaching an intra-day high of $6.99 (market cap of $1.29B) on 09/13/18, Johnson & Johnson-owned … read more...

Geron: A Very Long Wait For A Very Long Shot

via: SeekingAlpha at 2019-05-03 05:57:55:000

After Geron's ( GERN ) stock price experienced a meteoric rise and equally spectacular fall in the second half of 2018, it appears as though the stock might finally be about to stabilize. After reaching an intra-day high of $6.99 (market cap of $1.29B) on 09/13/18, Johnson & Johnson-owned … read more...

Geron EPS in-line, misses on revenue

via: SeekingAlpha at 2019-05-02 13:06:52:000

Geron (NASDAQ: GERN ): Q1 GAAP EPS of -$0.05 in-line. More news on: Geron Corporation, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Geron: On The Move Again

via: SeekingAlpha at 2019-04-09 21:59:37:000

Geron ( GERN ) is a stock that endured extreme turbulence during the closing months of 2018. I chronicled its saga with a series of articles advancing the bull side of an acknowledged binary outcome matrix; the opposite side prevailed as described in " Geron's Last Hurrah ?" This article des… read more...

Geron: On The Move Again

via: SeekingAlpha at 2019-04-09 21:59:37:000

Geron ( GERN ) is a stock that endured extreme turbulence during the closing months of 2018. I chronicled its saga with a series of articles advancing the bull side of an acknowledged binary outcome matrix; the opposite side prevailed as described in " Geron's Last Hurrah ?" This article des… read more...

Geron: On The Move Again

via: SeekingAlpha at 2019-04-09 21:59:37:000

Geron ( GERN ) is a stock that endured extreme turbulence during the closing months of 2018. I chronicled its saga with a series of articles advancing the bull side of an acknowledged binary outcome matrix; the opposite side prevailed as described in " Geron's Last Hurrah ?" This article des… read more...

Geron (GERN) Presents At 18th Annual Needham Healthcare Conference - Slideshow

via: SeekingAlpha at 2019-04-09 11:49:40:000

The following slide deck was published by Geron Corporation in conjunction with this Read more … read more...

FARO, HOLI, ZGNX and FIXX among notable midday movers

via: SeekingAlpha at 2019-04-09 08:44:41:000

Gainers: ATA (NASDAQ: ATAI ) +97% . Provention Bio (NASDAQ: PRVB ) +29% . PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +24% . Chimerix (NASDAQ: CMRX ) +22% . FARO Technologies (NASDAQ: FARO ) +17% . Soliton (NASDAQ: SOLY ) +15% . GEE Group (NYSEMKT: JOB ) +14% . Geron (NASDAQ: GERN ) … read more...

Needham likes Geron in premarket analyst action

via: SeekingAlpha at 2019-04-09 03:39:39:000

Ionis Pharmaceuticals (NASDAQ: IONS ) initiated with Neutral rating at Cantor Fitzgerald citing Spinraza headwinds. More news on: Ionis Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., Geron Corporation, Healthcare stocks news, Stocks on the move, , Read more … read more...

Disney+ And Bank Majors Step Out (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-04-07 03:37:15:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...

Disney+ And Bank Majors Step Out (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-04-07 03:37:15:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...

Stocks To Watch: Disney+ And Bank Majors Step Out

via: SeekingAlpha at 2019-04-06 04:39:00:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The week ahead sees a heavy dose of healthcare companies presenting at investor con… read more...

Geron Corporation's (GERN) CEO John Scarlett on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-07 16:52:04:000

Geron Corporation. (GERN) Q4 2018 Results Earnings Conference Call March 07, 2019, 04:30 PM ET Company Participants Suzanne Messere - Investor Relations John Scarlett - Chairman and CEO Olivia Bloom - Chief Financial Officer Conference Call Participants Chad Messer - Needha… read more...

Geron Corporation's (GERN) CEO John Scarlett on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-07 16:52:04:000

Geron Corporation. (GERN) Q4 2018 Results Earnings Conference Call March 07, 2019, 04:30 PM ET Company Participants Suzanne Messere - Investor Relations John Scarlett - Chairman and CEO Olivia Bloom - Chief Financial Officer Conference Call Participants Chad Messer - Needha… read more...

Geron Corporation's (GERN) CEO John Scarlett on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-07 16:52:04:000

Geron Corporation. (GERN) Q4 2018 Results Earnings Conference Call March 07, 2019, 04:30 PM ET Company Participants Suzanne Messere - Investor Relations John Scarlett - Chairman and CEO Olivia Bloom - Chief Financial Officer Conference Call Participants Chad Messer - Needha… read more...

Geron Corporation's (GERN) CEO John Scarlett on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-07 16:52:04:000

Geron Corporation. (GERN) Q4 2018 Results Earnings Conference Call March 07, 2019, 04:30 PM ET Company Participants Suzanne Messere - Investor Relations John Scarlett - Chairman and CEO Olivia Bloom - Chief Financial Officer Conference Call Participants Chad Messer - Needha… read more...

Geron Corporation's (GERN) CEO John Scarlett on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-07 16:52:04:000

Geron Corporation. (GERN) Q4 2018 Results Earnings Conference Call March 07, 2019, 04:30 PM ET Company Participants Suzanne Messere - Investor Relations John Scarlett - Chairman and CEO Olivia Bloom - Chief Financial Officer Conference Call Participants Chad Messer - Needha… read more...

Geron to transfer imetelstat program back by Q3

via: SeekingAlpha at 2019-03-07 11:32:56:000

Geron (NASDAQ: GERN ) Q4 results ($M): License fees/royalties: 0.4 (+96.3%). More news on: Geron Corporation, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

Geron EPS in-line, beats on revenue

via: SeekingAlpha at 2019-03-07 11:07:37:000

Geron (NASDAQ: GERN ): Q4 GAAP EPS of -$0.04 in-line. Revenue of $0.38M (+100.0% Y/Y) beats by $0.17M . Shares +1.4% . Press Release More news on: Geron Corporation, Earnings news and commentary, Stocks on the move, Healthcare stocks news, read more...

RNA Therapeutics: The Triumphant Return Of Biomolecular Mimetics

via: SeekingAlpha at 2019-03-07 07:36:51:000

Pain makes man think. Thought makes man wise. Wisdom makes life endurable. -John Patrick, Tea House of the August Moon There are few things in life more satisfying than the exhilarating thrill of discovery. Investing in ribonucleic acid ((RNA)) biotechnology does h… read more...

SOLO, DBD among premarket gainers

via: SeekingAlpha at 2019-02-13 09:19:41:000

Electrameccanica Vehicles (NASDAQ: SOLO ) +37% . More news on: Electrameccanica Vehicles Corp. Ltd., Diebold Nixdorf, Criteo S.A., Stocks on the move, Read more … read more...

SOLO, DBD among premarket gainers

via: SeekingAlpha at 2019-02-13 09:19:41:000

Electrameccanica Vehicles (NASDAQ: SOLO ) +37% . More news on: Electrameccanica Vehicles Corp. Ltd., Diebold Nixdorf, Criteo S.A., Stocks on the move, Read more … read more...

SOLO, DBD among premarket gainers

via: SeekingAlpha at 2019-02-13 09:19:41:000

Electrameccanica Vehicles (NASDAQ: SOLO ) +37% . More news on: Electrameccanica Vehicles Corp. Ltd., Diebold Nixdorf, Criteo S.A., Stocks on the move, Read more … read more...

Piper likes OncoCyte in premarket analyst action

via: SeekingAlpha at 2019-02-13 07:35:29:000

OncoCyte (NYSEMKT: OCX ) initiated with Buy rating and $6 (56% upside) price target at Piper Jaffray. Shares up 7% premarket. More news on: OncoCyte Corporation, Clovis Oncology, Galectin Therapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more … read more...

Piper likes OncoCyte in premarket analyst action

via: SeekingAlpha at 2019-02-13 07:35:29:000

OncoCyte (NYSEMKT: OCX ) initiated with Buy rating and $6 (56% upside) price target at Piper Jaffray. Shares up 7% premarket. More news on: OncoCyte Corporation, Clovis Oncology, Galectin Therapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more … read more...

Piper likes OncoCyte in premarket analyst action

via: SeekingAlpha at 2019-02-13 07:35:29:000

OncoCyte (NYSEMKT: OCX ) initiated with Buy rating and $6 (56% upside) price target at Piper Jaffray. Shares up 7% premarket. More news on: OncoCyte Corporation, Clovis Oncology, Galectin Therapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more … read more...

Geron's Imetelstat Likely To Gain 5 Years Of Patent Protection, Thanks To Janssen

via: SeekingAlpha at 2019-02-07 13:12:23:000

Investment Thesis Geron represents a compelling investment opportunity for growth-oriented investors with a tolerance for risk. Geron's share price has been trading close to the company's cash value following Janssen's decision to discontinue their Imetelstat development program. The myel… read more...

Geron's Imetelstat Likely To Gain 5 Years Of Patent Protection, Thanks To Janssen

via: SeekingAlpha at 2019-02-07 13:12:23:000

Investment Thesis Geron represents a compelling investment opportunity for growth-oriented investors with a tolerance for risk. Geron's share price has been trading close to the company's cash value following Janssen's decision to discontinue their Imetelstat development program. The myel… read more...

Geron's Imetelstat Likely To Gain 5 Years Of Patent Protection, Thanks To Janssen

via: SeekingAlpha at 2019-02-07 13:12:23:000

Investment Thesis Geron represents a compelling investment opportunity for growth-oriented investors with a tolerance for risk. Geron's share price has been trading close to the company's cash value following Janssen's decision to discontinue their Imetelstat development program. The myel… read more...

GERN, SYMC among premarket gainers

via: SeekingAlpha at 2019-02-01 09:13:57:000

Titan Pharmaceuticals (NASDAQ: TTNP ) +77% as it lauds Probuphine relaunch. More news on: Titan Pharmaceuticals, Inc., ToughBuilt Industries, Inc., Geron Corporation, Stocks on the move, , Read more … read more...

GERN, SYMC among premarket gainers

via: SeekingAlpha at 2019-02-01 09:13:57:000

Titan Pharmaceuticals (NASDAQ: TTNP ) +77% as it lauds Probuphine relaunch. More news on: Titan Pharmaceuticals, Inc., ToughBuilt Industries, Inc., Geron Corporation, Stocks on the move, , Read more … read more...

GERN, SYMC among premarket gainers

via: SeekingAlpha at 2019-02-01 09:13:57:000

Titan Pharmaceuticals (NASDAQ: TTNP ) +77% as it lauds Probuphine relaunch. More news on: Titan Pharmaceuticals, Inc., ToughBuilt Industries, Inc., Geron Corporation, Stocks on the move, , Read more … read more...

GERN, SYMC among premarket gainers

via: SeekingAlpha at 2019-02-01 09:13:57:000

Titan Pharmaceuticals (NASDAQ: TTNP ) +77% as it lauds Probuphine relaunch. More news on: Titan Pharmaceuticals, Inc., ToughBuilt Industries, Inc., Geron Corporation, Stocks on the move, , Read more … read more...

GERN, SYMC among premarket gainers

via: SeekingAlpha at 2019-02-01 09:13:57:000

Titan Pharmaceuticals (NASDAQ: TTNP ) +77% as it lauds Probuphine relaunch. More news on: Titan Pharmaceuticals, Inc., ToughBuilt Industries, Inc., Geron Corporation, Stocks on the move, , Read more … read more...

January Barometer Shows Momentum And Forensic Negative Portfolios Are The Hottest

via: SeekingAlpha at 2019-01-31 23:47:35:000

The Portfolio Barometer Using an inductive portfolio model approach that goes where the types of returns in the market are strongest, I monitor different fundamental, value, momentum, forensic, and anomaly portfolios from financial research to create a portfolio barometer. This article conti… read more...

January Barometer Shows Momentum And Forensic Negative Portfolios Are The Hottest

via: SeekingAlpha at 2019-01-31 23:47:35:000

The Portfolio Barometer Using an inductive portfolio model approach that goes where the types of returns in the market are strongest, I monitor different fundamental, value, momentum, forensic, and anomaly portfolios from financial research to create a portfolio barometer. This article conti… read more...

January Barometer Shows Momentum And Forensic Negative Portfolios Are The Hottest

via: SeekingAlpha at 2019-01-31 23:47:35:000

The Portfolio Barometer Using an inductive portfolio model approach that goes where the types of returns in the market are strongest, I monitor different fundamental, value, momentum, forensic, and anomaly portfolios from financial research to create a portfolio barometer. This article conti… read more...

January Barometer Shows Momentum And Forensic Negative Portfolios Are The Hottest

via: SeekingAlpha at 2019-01-31 23:47:35:000

The Portfolio Barometer Using an inductive portfolio model approach that goes where the types of returns in the market are strongest, I monitor different fundamental, value, momentum, forensic, and anomaly portfolios from financial research to create a portfolio barometer. This article conti… read more...

January Barometer Shows Momentum And Forensic Negative Portfolios Are The Hottest

via: SeekingAlpha at 2019-01-31 23:47:35:000

The Portfolio Barometer Using an inductive portfolio model approach that goes where the types of returns in the market are strongest, I monitor different fundamental, value, momentum, forensic, and anomaly portfolios from financial research to create a portfolio barometer. This article conti… read more...

FB, GE, VLO among premarket gainers

via: SeekingAlpha at 2019-01-31 09:19:45:000

Fortress Biotech (NASDAQ: FBIO ) +56% on Caelum deal with Alexion. More news on: Fortress Biotech, Inc., Prana Biotechnology Ltd, VistaGen Therapeutics, Inc., Stocks on the move, , Read more … read more...

B. Riley FBR likes Geron in premarket analyst action

via: SeekingAlpha at 2019-01-31 08:28:59:000

Supernus Pharmaceuticals (NASDAQ: SUPN ) resumed with Buy rating and $55 (48% upside) price target at Janney. More news on: Supernus Pharmaceuticals, Inc., Mesoblast, Geron Corporation, Healthcare stocks news, Stocks on the move, , Read more … read more...

GERN, BBBY among premarket gainers

via: SeekingAlpha at 2019-01-10 09:21:53:000

Inpixon (NASDAQ: INPX ) +36% chosen for planned smart school safety network. More news on: Inpixon, Gridsum Holding, Veritone, Stocks on the move, , Read more … read more...

GERN, BBBY among premarket gainers

via: SeekingAlpha at 2019-01-10 09:21:53:000

Inpixon (NASDAQ: INPX ) +36% chosen for planned smart school safety network. More news on: Inpixon, Gridsum Holding, Veritone, Stocks on the move, , Read more … read more...

GERN, BBBY among premarket gainers

via: SeekingAlpha at 2019-01-10 09:21:53:000

Inpixon (NASDAQ: INPX ) +36% chosen for planned smart school safety network. More news on: Inpixon, Gridsum Holding, Veritone, Stocks on the move, , Read more … read more...

Geron And The Winter Ahead

via: SeekingAlpha at 2018-12-24 12:03:29:000

The recent investor conference /ASH presentation provided additional data for Geron's (GERN) myelofibrosis ((MF)) and myelodysplastic syndromes ((MDS)) trials. The overall results of both trials were largely positive with no major surprises that deviated from the abstracts released in Novembe… read more...

Geron And The Winter Ahead

via: SeekingAlpha at 2018-12-24 12:03:29:000

The recent investor conference /ASH presentation provided additional data for Geron's (GERN) myelofibrosis ((MF)) and myelodysplastic syndromes ((MDS)) trials. The overall results of both trials were largely positive with no major surprises that deviated from the abstracts released in Novembe… read more...

Geron And The Winter Ahead

via: SeekingAlpha at 2018-12-24 12:03:29:000

The recent investor conference /ASH presentation provided additional data for Geron's (GERN) myelofibrosis ((MF)) and myelodysplastic syndromes ((MDS)) trials. The overall results of both trials were largely positive with no major surprises that deviated from the abstracts released in Novembe… read more...

Geron And The Winter Ahead

via: SeekingAlpha at 2018-12-24 12:03:29:000

The recent investor conference /ASH presentation provided additional data for Geron's (GERN) myelofibrosis ((MF)) and myelodysplastic syndromes ((MDS)) trials. The overall results of both trials were largely positive with no major surprises that deviated from the abstracts released in Novembe… read more...

Geron Corporation (GERN) CEO John Scarlett Hosts Analyst and Investor Event (Transcript)

via: SeekingAlpha at 2018-12-10 20:25:05:000

Geron Corporation (GERN) Analyst and Investor Event Conference Call December 10, 2018 8:00 AM ET Executives Suzanne Messere - Investor Relations John Scarlett - President and CEO John Mascarenhas - Icahn School of Medicine, Mount Sinai, New York Azra Raza - New York-Presbyteri… read more...

Geron Corporation (GERN) CEO John Scarlett Hosts Analyst and Investor Event (Transcript)

via: SeekingAlpha at 2018-12-10 20:25:05:000

Geron Corporation (GERN) Analyst and Investor Event Conference Call December 10, 2018 8:00 AM ET Executives Suzanne Messere - Investor Relations John Scarlett - President and CEO John Mascarenhas - Icahn School of Medicine, Mount Sinai, New York Azra Raza - New York-Presbyteri… read more...

Geron Corporation (GERN) Investor Presentation - Slideshow

via: SeekingAlpha at 2018-12-10 13:17:48:000

The following slide deck was published by Geron Corporation in conjunction with this Read more … read more...

Geron: What Happened At ASH?

via: SeekingAlpha at 2018-12-10 10:18:52:000

Thesis Geron ( GERN ) has presented new data at the American Society of Hematology ((ASH)) meeting in San Diego a couple of days ago. Geron's Imetelstat has shown solid results in the phase II portion of phase II/III study IMerge, and Geron has stated that these results support the investiga… read more...

Geron (GERN) Presents At Piper Jaffray 30th Annual Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-11-28 14:30:43:000

The following slide deck was published by Geron Corporation in conjunction with this Read more … read more...

Geron (GERN) Presents At Piper Jaffray 30th Annual Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-11-28 14:30:43:000

The following slide deck was published by Geron Corporation in conjunction with this Read more … read more...

Geron (GERN) Presents At Piper Jaffray 30th Annual Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-11-28 14:30:43:000

The following slide deck was published by Geron Corporation in conjunction with this Read more … read more...

Geron Corporation (GERN) CEO John Scarlett Presents at Annual Piper Jaffray Healthcare Conference Call Transcript

via: SeekingAlpha at 2018-11-27 17:50:59:000

Geron Corporation (GERN) Annual Piper Jaffray Healthcare Conference Call November 27, 2018 11:30 ET Executives John Scarlett - President & CEO Analysts Danielle Brill - Piper Jaffray Presentation Danielle Brill Good afternoon, everyone. I'm Danielle Brill, one of … read more...

Cancer Research Highlight: AbbVie And Pfizer Blitz Acute Myeloid Leukemia

via: SeekingAlpha at 2018-11-27 08:00:00:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Until very recently, patients … read more...

Geron Corporation (GERN) CEO John Scarlett Presents at Stifel 2018 Healthcare Conference Call Transcript

via: SeekingAlpha at 2018-11-14 19:49:15:000

Geron Corporation (GERN) Stifel 2018 Healthcare Conference Call November 14, 2018 2 PM ET Executives Steve Klass - Biotech Equity Research Associate at Stifel Financial Corp John Scarlett - President and Chief Executive Officer Presentation Steve Klass I'm Steve Klass, on… read more...

Geron Corporation (GERN) CEO John Scarlett Presents at Stifel 2018 Healthcare Conference Call Transcript

via: SeekingAlpha at 2018-11-14 19:49:15:000

Geron Corporation (GERN) Stifel 2018 Healthcare Conference Call November 14, 2018 2 PM ET Executives Steve Klass - Biotech Equity Research Associate at Stifel Financial Corp John Scarlett - President and Chief Executive Officer Presentation Steve Klass I'm Steve Klass, on… read more...

Geron Corporation (GERN) CEO John Scarlett Presents at Stifel 2018 Healthcare Conference Call Transcript

via: SeekingAlpha at 2018-11-14 19:49:15:000

Geron Corporation (GERN) Stifel 2018 Healthcare Conference Call November 14, 2018 2 PM ET Executives Steve Klass - Biotech Equity Research Associate at Stifel Financial Corp John Scarlett - President and Chief Executive Officer Presentation Steve Klass I'm Steve Klass, on… read more...

Geron: Of Abstracts And Abstractions

via: SeekingAlpha at 2018-11-09 12:21:17:000

With the recent release of the ASH abstracts and GERN's conference call, a flicker of light has been shed on the situation. GERN has managed to obtain two oral presentations for their trials in myelofibrosis (MF) and myelodysplastic syndrome (NYSE: MDS ), indicating that the reviewers believe … read more...

Geron: Of Abstracts And Abstractions

via: SeekingAlpha at 2018-11-09 12:21:17:000

With the recent release of the ASH abstracts and GERN's conference call, a flicker of light has been shed on the situation. GERN has managed to obtain two oral presentations for their trials in myelofibrosis (MF) and myelodysplastic syndrome (NYSE: MDS ), indicating that the reviewers believe … read more...

Geron: Of Abstracts And Abstractions

via: SeekingAlpha at 2018-11-09 12:21:17:000

With the recent release of the ASH abstracts and GERN's conference call, a flicker of light has been shed on the situation. GERN has managed to obtain two oral presentations for their trials in myelofibrosis (MF) and myelodysplastic syndrome (NYSE: MDS ), indicating that the reviewers believe … read more...

Geron: Of Abstracts And Abstractions

via: SeekingAlpha at 2018-11-09 12:21:17:000

With the recent release of the ASH abstracts and GERN's conference call, a flicker of light has been shed on the situation. GERN has managed to obtain two oral presentations for their trials in myelofibrosis (MF) and myelodysplastic syndrome (NYSE: MDS ), indicating that the reviewers believe … read more...

Geron: Of Abstracts And Abstractions

via: SeekingAlpha at 2018-11-09 12:21:17:000

With the recent release of the ASH abstracts and GERN's conference call, a flicker of light has been shed on the situation. GERN has managed to obtain two oral presentations for their trials in myelofibrosis (MF) and myelodysplastic syndrome (NYSE: MDS ), indicating that the reviewers believe … read more...

Geron's Last Hurrah?

via: SeekingAlpha at 2018-11-05 07:53:27:000

I have vacillated in titling this article. I started to write it in the glow of the 11/1/18 ASH news run-up (release of ASH presentation transcripts) in stock price. As I started to write this posting on 11/1/18, I tentatively titled it: "Geron, The Comeback Kid?". After I listened to Geron's … read more...

Geron's Last Hurrah?

via: SeekingAlpha at 2018-11-05 07:53:27:000

I have vacillated in titling this article. I started to write it in the glow of the 11/1/18 ASH news run-up (release of ASH presentation transcripts) in stock price. As I started to write this posting on 11/1/18, I tentatively titled it: "Geron, The Comeback Kid?". After I listened to Geron's … read more...

Geron's Last Hurrah?

via: SeekingAlpha at 2018-11-05 07:53:27:000

I have vacillated in titling this article. I started to write it in the glow of the 11/1/18 ASH news run-up (release of ASH presentation transcripts) in stock price. As I started to write this posting on 11/1/18, I tentatively titled it: "Geron, The Comeback Kid?". After I listened to Geron's … read more...

Cancer Research Highlight: Geron Looks To Get Digging Out Of 2018

via: SeekingAlpha at 2018-11-02 08:00:00:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Much ink has been spilled ab… read more...

Cancer Research Highlight: Geron Looks To Get Digging Out Of 2018

via: SeekingAlpha at 2018-11-02 08:00:00:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Much ink has been spilled ab… read more...

Cancer Research Highlight: Geron Looks To Get Digging Out Of 2018

via: SeekingAlpha at 2018-11-02 08:00:00:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Much ink has been spilled ab… read more...

Geron's (GERN) CEO Dr. John Scarlett on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-01 21:14:05:000

Geron Corporation (NASDAQ:GERN) Q3 2018 Earnings Conference Call November 1, 2018 4:30 PM ET Executives Suzanne Messere - Investor Relations Dr. John Scarlett - President and CEO Olivia Bloom - Chief Financial Officer Analysts George Zavoico - B. Riley FBR Presentation… read more...

Geron's (GERN) CEO Dr. John Scarlett on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-01 21:14:05:000

Geron Corporation (NASDAQ:GERN) Q3 2018 Earnings Conference Call November 1, 2018 4:30 PM ET Executives Suzanne Messere - Investor Relations Dr. John Scarlett - President and CEO Olivia Bloom - Chief Financial Officer Analysts George Zavoico - B. Riley FBR Presentation… read more...

Geron's (GERN) CEO Dr. John Scarlett on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-01 21:14:05:000

Geron Corporation (NASDAQ:GERN) Q3 2018 Earnings Conference Call November 1, 2018 4:30 PM ET Executives Suzanne Messere - Investor Relations Dr. John Scarlett - President and CEO Olivia Bloom - Chief Financial Officer Analysts George Zavoico - B. Riley FBR Presentation… read more...

Geron Q3 cash balance up 75%

via: SeekingAlpha at 2018-11-01 16:13:17:000

Geron (NASDAQ: GERN ) Q3 results ($M): Revenue: 0.2 (+1.2%). More news on: Geron Corporation, Healthcare stocks news, Earnings news and commentary, Read more … read more...

Geron beats by $0.02, misses on revenue

via: SeekingAlpha at 2018-11-01 16:08:46:000

Geron (NASDAQ: GERN ): Q3 GAAP EPS of -$0.03 beats by $0.02 . Revenue of $0.17M (+6.3% Y/Y) misses by $0.04M . Cash and equivalents $184.8M. Press Release More news on: Geron Corporation, Earnings news and commentary, Healthcare stocks news, read more...

Geron: What To Expect From This Embattled Biotech?

via: SeekingAlpha at 2018-11-01 11:01:55:000

Editor's note: Seeking Alpha is proud to welcome All North Ventures as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Aft… read more...

BT, NXPI among top gainers

via: SeekingAlpha at 2018-11-01 09:27:15:000

SELLAS Life Sciences (NASDAQ: SLS ) +20% on positive analyst action . More news on: SELLAS Life Sciences Group, Inc., Attunity Ltd, Floor & Decor Holdings, Inc., Stocks on the move, , Top stock market news, Read more … read more...

Apple Looks To Recharge Tech Sector (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-10-28 09:11:09:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look for… read more...

Apple Looks To Recharge Tech Sector (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-10-28 09:11:09:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look for… read more...

Apple Looks To Recharge Tech Sector (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-10-28 09:11:09:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look for… read more...

Apple Looks To Recharge Tech Sector

via: SeekingAlpha at 2018-10-27 08:44:22:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors are being put to the rest with major indexes now down sharply on the year… read more...

Geron: Sifting Through The Pieces

via: SeekingAlpha at 2018-10-09 11:29:37:000

Editor's note: Seeking Alpha is proud to welcome BioTrench as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Following a cl… read more...

Geron: Sifting Through The Pieces

via: SeekingAlpha at 2018-10-09 11:29:37:000

Editor's note: Seeking Alpha is proud to welcome BioTrench as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Following a cl… read more...

Geron: Sifting Through The Pieces

via: SeekingAlpha at 2018-10-09 11:29:37:000

Editor's note: Seeking Alpha is proud to welcome BioTrench as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Following a cl… read more...

Geron's Biggest Problem Still Lies Ahead

via: SeekingAlpha at 2018-10-09 00:03:43:000

Introduction According to its website , We are a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Recently, Geron ( GERN ) announced Janssen's intention to discontinue its partnership in t… read more...

Geron's Biggest Problem Still Lies Ahead

via: SeekingAlpha at 2018-10-09 00:03:43:000

Introduction According to its website , We are a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Recently, Geron ( GERN ) announced Janssen's intention to discontinue its partnership in t… read more...

Geron's Biggest Problem Still Lies Ahead

via: SeekingAlpha at 2018-10-09 00:03:43:000

Introduction According to its website , We are a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Recently, Geron ( GERN ) announced Janssen's intention to discontinue its partnership in t… read more...

Geron After The Janssen Decision - Hold Or Fold?

via: SeekingAlpha at 2018-10-03 09:03:45:000

Thesis Johnson & Johnson's Janssen ( JNJ ) has decided against a continuation of its collaboration with Geron ( GERN ). This announcement, which was made a couple of days ago, has sent Geron's shares to a new 5-year low. Geron will have to move forward alone over the coming years if it… read more...

Geron After The Janssen Decision - Hold Or Fold?

via: SeekingAlpha at 2018-10-03 09:03:45:000

Thesis Johnson & Johnson's Janssen ( JNJ ) has decided against a continuation of its collaboration with Geron ( GERN ). This announcement, which was made a couple of days ago, has sent Geron's shares to a new 5-year low. Geron will have to move forward alone over the coming years if it… read more...

Geron After The Janssen Decision - Hold Or Fold?

via: SeekingAlpha at 2018-10-03 09:03:45:000

Thesis Johnson & Johnson's Janssen ( JNJ ) has decided against a continuation of its collaboration with Geron ( GERN ). This announcement, which was made a couple of days ago, has sent Geron's shares to a new 5-year low. Geron will have to move forward alone over the coming years if it… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-10-02 07:30:09:000

National Vision (NASDAQ: EYE ) initiated with Equal Weight rating and $50 (12% upside) price target at Barclays. More news on: National Vision Holdings, Inovio Pharmaceuticals, Inc., Theratechnologies Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Geron: Interesting Times

via: SeekingAlpha at 2018-10-02 03:04:25:000

Geron ( GERN ) has been wandering in the wilderness for these last four years as shown by its price chart below: GERN data by YCharts Geron and a Johnson & Johnson (NYSE: JNJ ) subsidiary Janssen signed a collaboration agreement ((CA)) focused on Geron's telomerase inhibitor imete… read more...

Premarket Losers as of 9:05 am (10/1/2018)

via: SeekingAlpha at 2018-10-01 09:08:39:000

RXII -49% on pricing $15M public offering. More news on: RXI Pharmaceuticals Corporation, Infinera Corporation, Uranium Energy Corp, Stocks on the move, Top stock market news, , Read more … read more...

INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Geron Corp.

via: Business Wire at 2018-09-28 21:15:00:000

The law firm of Kirby McInerney LLP is investigating potential claims against Geron Corporation (Geron or the Company) (NASDAQ: GERN). This investigation concerns whether Geron has violated federal securities laws and/or engaged in other unlawful business pr… read more...

INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Geron Corp.

via: Business Wire at 2018-09-28 21:15:00:000

The law firm of Kirby McInerney LLP is investigating potential claims against Geron Corporation (Geron or the Company) (NASDAQ: GERN). This investigation concerns whether Geron has violated federal securities laws and/or engaged in other unlawful business pr… read more...

Midday Gainers / Losers (09/28/2018)

via: SeekingAlpha at 2018-09-28 12:40:43:000

Gainers: SYN +207% . IGC +36% . NBEV +31% . AYTU +23% . ZN +21% . CCXI +17% . IMMP +14% . SPNS +14% . PRSS +13% . AC +12% . More news on: Synthetic Biologics, Inc., India Globalization Capital, Inc, New Age Beverages Corporation, Stocks on the move, , Top s… read more...

Premarket Losers as of 9:05 am (9/28/2018)

via: SeekingAlpha at 2018-09-28 09:15:12:000

ALT -48% on pricing $12M Public Offering. More news on: Altimmune, Inc., Geron Corporation, Stocks on the move, Top stock market news, , Read more … read more...

The Screen That Kept My Subscribers Out Of Geron

via: SeekingAlpha at 2018-09-28 06:58:44:000

Geron's telomerase inhibitor Imetelstatin in action (Credit: Geron ) The Screen That Kept Our Subscribers Out Of Geron We know the bad news about Geron Corporation ( GERN ) now. We didn't know it back in April though, when I noted that it didn't pass one of Portfolio Armor's initia… read more...

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Geron Corporation (GERN)

via: PR Newswire at 2018-09-27 14:48:00:000

NEW YORK , Sept. 27, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN). Such investors are encouraged to obtain additional information… read more...

Head-To-Head: Geron's Imetelstat Versus Acceleron's Luspatarcept For MDS

via: SeekingAlpha at 2018-09-27 14:11:48:000

Figure 1: Geron and Acceleron battle for the MDS market, but who is likely to be victorious? Introduction Geron ( GERN ), in collaboration with Janssen ( JNJ ), is developing Imetelstat for Myelodysplastic syndrome [MDS] and Myelofibrosis [MF]. The following article will compare Gero… read more...

Geron's (GERN) CEO John Scarlett on Update on Imetelstat Collaboration with Janssen - Transcript

via: SeekingAlpha at 2018-09-27 13:24:15:000

Geron Corporation (GERN) Update on Imetelstat Collaboration with Janssen September 27, 2018 8:00 AM ET Executives San Messere Investor Relations John Scarlett President and Chief Executive Officer Olivia Bloom Chief Financial Officer Analysts Chad… read more...

Midday Gainers / Losers (09/27/2018)

via: SeekingAlpha at 2018-09-27 12:40:42:000

Gainers: ACHV +58% . RXII +36% . IGC +26% . GBR +25% . HAIR +20% . YGYI +18% . NTGN +17% . LQDA +16% . ARAY +17% . CCJ +16% . More news on: Achieve Life Sciences, Inc., RXI Pharmaceuticals Corporation, India Globalization Capital, Inc, Stocks on the mo… read more...

Geron Corp. (GERN) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

via: PR Newswire at 2018-09-27 11:57:00:000

BOSTON , Sept. 27, 2018 /PRNewswire/ --Block & Leviton LLP ( www.blockesq.com ), a securities litigation firm representing investors nationwide, is investigating whether Geron Corporation. ("Geron" or the "Company") (NASDAQ: GERN) and certain of its officers and directors violat… read more...

Investor Alert: Kaplan Fox Investigates Geron Corporation

via: PR Newswire at 2018-09-27 10:00:00:000

NEW YORK , Sept. 27, 2018 /PRNewswire/ --Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) has been investigating claims on behalf of investors of Menlo park, California -based Geron Corporation ("Geron" or the "Company") (Nasdaq: GERN). On September 27, 2018 , before… read more...

Premarket Losers as of 9:05 am (9/27/2018)

via: SeekingAlpha at 2018-09-27 09:11:25:000

GERN -69% on announcing discontinuation of Imetelstat collaboration by Janssen. More news on: Geron Corporation, Bed Bath & Beyond Inc., Comtech Telecommunications Corp., Stocks on the move, , Top stock market news, Read more … read more...

Shares of biotech firm Geron fall 70% after Johnson & Johnson ends collaboration

via: CNBC at 2018-09-27 08:20:00:000

No summary available. read more...

Geron announces discontinuation of Imetelstat collaboration by Janssen; shares down 68% premarket

via: SeekingAlpha at 2018-09-27 06:39:28:000

Geron Corporation (NASDAQ: GERN ) announces that Janssen Biotech has terminated the 2014 Collaboration and License Agreement (CLA) with the Company. The decision was made as the result of a strategic portfolio evaluation and prioritization of assets within their portfolio. More news on: … read more...

Geron to update investors tomorrow on imetelstat deal with Janssen; shares down 2% after hours

via: SeekingAlpha at 2018-09-26 21:26:43:000

Geron (NASDAQ: GERN ) will host a conference call tomorrow, September 27, at 8:00 am ET to update investors on its imetelstat development deal with Johnson & Johnson's (NYSE: JNJ ) Janssen unit. More news on: Geron Corporation, Johnson & Johnson, Healthcare stocks news, Stocks on… read more...

Geron: How To Play The Imetelstat Catalyst

via: SeekingAlpha at 2018-09-26 09:30:09:000

Thesis Geron's ( GERN ) Imetelstat is being evaluated for several indications right now . Johnson & Johnson's ( JNJ ) Janssen will have to make a decision on whether to continue with its collaboration agreement, and that decision will come during the next couple of days. A contin… read more...

Premarket Gainers as of 9:05 am (09/25/2018)

via: SeekingAlpha at 2018-09-25 09:19:16:000

JONE +47% . More news on: Jones Energy, Inc., Applied DNA Sciences, Inc., Clean Diesel Technologies, Inc., Stocks on the move, , Top stock market news, Read more … read more...

Geron: The Last Chapter

via: SeekingAlpha at 2018-09-21 05:11:15:000

Geron (GERN) has one therapy, imetelstat, currently in clinical trials for treatment of two serious hematological cancers. The first trial is IMbark for Myelofibrosis ((MF)), the second is IMerge for Myelodysplastic Syndrome ((MDS)). There are indications that a third trial for AML is the … read more...

Geron: The Last Chapter

via: SeekingAlpha at 2018-09-21 05:11:15:000

Geron (GERN) has one therapy, imetelstat, currently in clinical trials for treatment of two serious hematological cancers. The first trial is IMbark for Myelofibrosis ((MF)), the second is IMerge for Myelodysplastic Syndrome ((MDS)). There are indications that a third trial for AML is the … read more...

Geron: The Last Chapter

via: SeekingAlpha at 2018-09-21 05:11:15:000

Geron (GERN) has one therapy, imetelstat, currently in clinical trials for treatment of two serious hematological cancers. The first trial is IMbark for Myelofibrosis ((MF)), the second is IMerge for Myelodysplastic Syndrome ((MDS)). There are indications that a third trial for AML is the … read more...

Geron: The Last Chapter

via: SeekingAlpha at 2018-09-21 05:11:15:000

Geron (GERN) has one therapy, imetelstat, currently in clinical trials for treatment of two serious hematological cancers. The first trial is IMbark for Myelofibrosis ((MF)), the second is IMerge for Myelodysplastic Syndrome ((MDS)). There are indications that a third trial for AML is the … read more...

Surviving The Geron Roller Coaster As An Investor

via: SeekingAlpha at 2018-09-19 08:00:00:000

There is no other company that quite captures one's imagination like Geron Corp ( GERN ), the venerable darling of hopeful investors both long and short. One on hand, they've undergone a remarkable transition from being a regenerative medicine company into a full-blown cancer therapy developer… read more...

Surviving The Geron Roller Coaster As An Investor

via: SeekingAlpha at 2018-09-19 08:00:00:000

There is no other company that quite captures one's imagination like Geron Corp ( GERN ), the venerable darling of hopeful investors both long and short. One on hand, they've undergone a remarkable transition from being a regenerative medicine company into a full-blown cancer therapy developer… read more...

Geron's Big Day

via: SeekingAlpha at 2018-09-14 14:59:36:000

Johnson & Johnson's ( JNJ ) subsidiary Janssen is giving Geron's ( GERN ) imetelstat a thorough review preparatory to making a key continuation decision under its 2014 collaboration agreement with Geron. This posting focuses on today's (9/13/18) place in advancing the Geron story. My … read more...

Geron's Big Day

via: SeekingAlpha at 2018-09-14 14:59:36:000

Johnson & Johnson's ( JNJ ) subsidiary Janssen is giving Geron's ( GERN ) imetelstat a thorough review preparatory to making a key continuation decision under its 2014 collaboration agreement with Geron. This posting focuses on today's (9/13/18) place in advancing the Geron story. My … read more...

Geron's Big Day

via: SeekingAlpha at 2018-09-14 14:59:36:000

Johnson & Johnson's ( JNJ ) subsidiary Janssen is giving Geron's ( GERN ) imetelstat a thorough review preparatory to making a key continuation decision under its 2014 collaboration agreement with Geron. This posting focuses on today's (9/13/18) place in advancing the Geron story. My … read more...

Geron's Big Day

via: SeekingAlpha at 2018-09-14 14:59:36:000

Johnson & Johnson's ( JNJ ) subsidiary Janssen is giving Geron's ( GERN ) imetelstat a thorough review preparatory to making a key continuation decision under its 2014 collaboration agreement with Geron. This posting focuses on today's (9/13/18) place in advancing the Geron story. My … read more...

Geron's Big Day

via: SeekingAlpha at 2018-09-14 14:59:36:000

Johnson & Johnson's ( JNJ ) subsidiary Janssen is giving Geron's ( GERN ) imetelstat a thorough review preparatory to making a key continuation decision under its 2014 collaboration agreement with Geron. This posting focuses on today's (9/13/18) place in advancing the Geron story. My … read more...

Geron down 11% on uncertainty with imetelstat with Janssen

via: SeekingAlpha at 2018-09-13 11:47:53:000

Geron ( GERN -11.2% ), up 22% earlier, is now in the red on more than triple normal volume in apparent reaction to the lack of a decision from Johnson & Johnson on continuing with imetelstat. Investors appeared to be jumping the gun ahead of J&J's pharma update this mor… read more...

Premarket Gainers as of 9:15 am (9/13/2018)

via: SeekingAlpha at 2018-09-13 09:27:19:000

PI +39% on Q2 earnings . More news on: Impinj, Inc., Geron Corporation, GNC Holdings, Inc., Stocks on the move, , Read more … read more...

2 Approaches To BioPharma: Interview With TPT Collaborators Amit Ghate And Zach Hartman

via: SeekingAlpha at 2018-09-10 13:10:06:000

Thanks for joining us today! Welcome to Dr Zach Hartman and Amit Ghate , two well-known analysts on SeekingAlpha, and very luckily for us here at the Total Pharma Tracker , our two outstanding collaborators. Amit has a mostly short-focused style, and he dabbles in the biopharma sector … read more...

2 Approaches To BioPharma: Interview With TPT Collaborators Amit Ghate And Zach Hartman

via: SeekingAlpha at 2018-09-10 13:10:06:000

Thanks for joining us today! Welcome to Dr Zach Hartman and Amit Ghate , two well-known analysts on SeekingAlpha, and very luckily for us here at the Total Pharma Tracker , our two outstanding collaborators. Amit has a mostly short-focused style, and he dabbles in the biopharma sector … read more...

2 Approaches To BioPharma: Interview With TPT Collaborators Amit Ghate And Zach Hartman

via: SeekingAlpha at 2018-09-10 13:10:06:000

Thanks for joining us today! Welcome to Dr Zach Hartman and Amit Ghate , two well-known analysts on SeekingAlpha, and very luckily for us here at the Total Pharma Tracker , our two outstanding collaborators. Amit has a mostly short-focused style, and he dabbles in the biopharma sector … read more...

Geron: A September To Remember

via: SeekingAlpha at 2018-09-07 12:11:10:000

Geron ( GERN ) is my top biotech speculative holding. I strongly recommend it for consideration for those who are willing to investigate its great near-term potential. I have written on several occasions about my expectation that it reach $10.00 by 10/10 . I'm mulling over a future articl… read more...

Geron: A September To Remember

via: SeekingAlpha at 2018-09-07 12:11:10:000

Geron ( GERN ) is my top biotech speculative holding. I strongly recommend it for consideration for those who are willing to investigate its great near-term potential. I have written on several occasions about my expectation that it reach $10.00 by 10/10 . I'm mulling over a future articl… read more...

Geron: A September To Remember

via: SeekingAlpha at 2018-09-07 12:11:10:000

Geron ( GERN ) is my top biotech speculative holding. I strongly recommend it for consideration for those who are willing to investigate its great near-term potential. I have written on several occasions about my expectation that it reach $10.00 by 10/10 . I'm mulling over a future articl… read more...

Premarket Gainers as of 9:05 am (9/4/2018)

via: SeekingAlpha at 2018-09-04 09:24:09:000

MNKD +47% on collaborating with United Therapeutics for pulmonary hypertension products. More news on: MannKind Corporation, TravelCenters of America LLC, Recro Pharma Inc, Stocks on the move, , Read more … read more...

Premarket Gainers as of 9:05 am (9/4/2018)

via: SeekingAlpha at 2018-09-04 09:24:09:000

MNKD +47% on collaborating with United Therapeutics for pulmonary hypertension products. More news on: MannKind Corporation, TravelCenters of America LLC, Recro Pharma Inc, Stocks on the move, , Read more … read more...

Premarket Gainers as of 9:05 am (9/4/2018)

via: SeekingAlpha at 2018-09-04 09:24:09:000

MNKD +47% on collaborating with United Therapeutics for pulmonary hypertension products. More news on: MannKind Corporation, TravelCenters of America LLC, Recro Pharma Inc, Stocks on the move, , Read more … read more...

Geron: Parsing $10 By 10/10

via: SeekingAlpha at 2018-09-03 06:39:58:000

I have enjoyed chronicling the twists and turns fate has parceled out to Geron's ( GERN ) investors. It has been a torturous journey for investors as Geron's collaboration agreement with Johnson & Johnson's ( JNJ ) subsidiary Janssen lurches forward to its next phase. The agreement covers … read more...

Geron: The Remarkable Data Desert

via: SeekingAlpha at 2018-08-28 09:51:42:000

Geron ( GERN ) is a sprightly thirty year old biotech that is awaiting big news. Johnson & Johnson's ( JNJ ) subsidiary Janssen is giving its imetelstat pipedot (Geron's pipeline has but this single therapy) a thorough review preparatory to making a key continuation decision under its… read more...

Geron: The Remarkable Data Desert

via: SeekingAlpha at 2018-08-28 09:51:42:000

Geron ( GERN ) is a sprightly thirty year old biotech that is awaiting big news. Johnson & Johnson's ( JNJ ) subsidiary Janssen is giving its imetelstat pipedot (Geron's pipeline has but this single therapy) a thorough review preparatory to making a key continuation decision under its… read more...

Geron: The Remarkable Data Desert

via: SeekingAlpha at 2018-08-28 09:51:42:000

Geron ( GERN ) is a sprightly thirty year old biotech that is awaiting big news. Johnson & Johnson's ( JNJ ) subsidiary Janssen is giving its imetelstat pipedot (Geron's pipeline has but this single therapy) a thorough review preparatory to making a key continuation decision under its… read more...

Midday Gainers / Losers (08/24/2018)

via: SeekingAlpha at 2018-08-24 12:37:29:000

Gainers: GERN +28% . SSC +27% . CVM +18% . SPLK +16% . CPIX +16% . CRON +16% . CNAT +15% . REED +15% . ADSK +15% . BRY +14% . More news on: Geron Corporation, Seven Stars Cloud Group, Inc., Cel-Sci Corporation, Stocks on the move, , Read more … read more...

Midday Gainers / Losers (08/24/2018)

via: SeekingAlpha at 2018-08-24 12:37:29:000

Gainers: GERN +28% . SSC +27% . CVM +18% . SPLK +16% . CPIX +16% . CRON +16% . CNAT +15% . REED +15% . ADSK +15% . BRY +14% . More news on: Geron Corporation, Seven Stars Cloud Group, Inc., Cel-Sci Corporation, Stocks on the move, , Read more … read more...

Midday Gainers / Losers (08/24/2018)

via: SeekingAlpha at 2018-08-24 12:37:29:000

Gainers: GERN +28% . SSC +27% . CVM +18% . SPLK +16% . CPIX +16% . CRON +16% . CNAT +15% . REED +15% . ADSK +15% . BRY +14% . More news on: Geron Corporation, Seven Stars Cloud Group, Inc., Cel-Sci Corporation, Stocks on the move, , Read more … read more...

Midday Gainers / Losers (08/24/2018)

via: SeekingAlpha at 2018-08-24 12:37:29:000

Gainers: GERN +28% . SSC +27% . CVM +18% . SPLK +16% . CPIX +16% . CRON +16% . CNAT +15% . REED +15% . ADSK +15% . BRY +14% . More news on: Geron Corporation, Seven Stars Cloud Group, Inc., Cel-Sci Corporation, Stocks on the move, , Read more … read more...

Geron up 42% on expectations of J&J continuing with imetelstat

via: SeekingAlpha at 2018-08-24 09:57:58:000

Geron ( GERN +42.2% ) is up on double normal volume in apparent response to a job posting for a pricing manager whose duties will include a setting a pricing approach for imetelstat, implying that its Janssen unit will continue development. More news on: Geron Corporation, Healthcare s… read more...

Geron up 42% on expectations of J&J continuing with imetelstat

via: SeekingAlpha at 2018-08-24 09:57:58:000

Geron ( GERN +42.2% ) is up on double normal volume in apparent response to a job posting for a pricing manager whose duties will include a setting a pricing approach for imetelstat, implying that its Janssen unit will continue development. More news on: Geron Corporation, Healthcare s… read more...

Geron up 42% on expectations of J&J continuing with imetelstat

via: SeekingAlpha at 2018-08-24 09:57:58:000

Geron ( GERN +42.2% ) is up on double normal volume in apparent response to a job posting for a pricing manager whose duties will include a setting a pricing approach for imetelstat, implying that its Janssen unit will continue development. More news on: Geron Corporation, Healthcare s… read more...

Geron up 42% on expectations of J&J continuing with imetelstat

via: SeekingAlpha at 2018-08-24 09:57:58:000

Geron ( GERN +42.2% ) is up on double normal volume in apparent response to a job posting for a pricing manager whose duties will include a setting a pricing approach for imetelstat, implying that its Janssen unit will continue development. More news on: Geron Corporation, Healthcare s… read more...

Geron: Short Stew Brewing

via: SeekingAlpha at 2018-08-24 01:22:00:000

Geron ( GERN ) presents a simple value proposition. If its contribution to cancer treatment can reel in the big fish that has been on its hook since 2014, Geron's investors will prosper. Otherwise not, or so the conventional thinking has been. This article will stick with the conventional th… read more...

Geron: Short Stew Brewing

via: SeekingAlpha at 2018-08-24 01:22:00:000

Geron ( GERN ) presents a simple value proposition. If its contribution to cancer treatment can reel in the big fish that has been on its hook since 2014, Geron's investors will prosper. Otherwise not, or so the conventional thinking has been. This article will stick with the conventional th… read more...

Geron: Short Stew Brewing

via: SeekingAlpha at 2018-08-24 01:22:00:000

Geron ( GERN ) presents a simple value proposition. If its contribution to cancer treatment can reel in the big fish that has been on its hook since 2014, Geron's investors will prosper. Otherwise not, or so the conventional thinking has been. This article will stick with the conventional th… read more...

Geron: Short Stew Brewing

via: SeekingAlpha at 2018-08-24 01:22:00:000

Geron ( GERN ) presents a simple value proposition. If its contribution to cancer treatment can reel in the big fish that has been on its hook since 2014, Geron's investors will prosper. Otherwise not, or so the conventional thinking has been. This article will stick with the conventional th… read more...

Geron: Shifting Sands On The High Dunes

via: SeekingAlpha at 2018-08-16 06:01:39:000

Geron's ( GERN ) pipedot , imetelstat, is undergoing critical scrutiny like never before. Johnson & Johnson's ( JNJ ) subsidiary Janssen is giving it a thorough review preparatory to making a key continuation decision under its 2014 collaboration agreement with Geron . Geron invest… read more...

Geron: Shifting Sands On The High Dunes

via: SeekingAlpha at 2018-08-16 06:01:39:000

Geron's ( GERN ) pipedot , imetelstat, is undergoing critical scrutiny like never before. Johnson & Johnson's ( JNJ ) subsidiary Janssen is giving it a thorough review preparatory to making a key continuation decision under its 2014 collaboration agreement with Geron . Geron invest… read more...

Geron: Shifting Sands On The High Dunes

via: SeekingAlpha at 2018-08-16 06:01:39:000

Geron's ( GERN ) pipedot , imetelstat, is undergoing critical scrutiny like never before. Johnson & Johnson's ( JNJ ) subsidiary Janssen is giving it a thorough review preparatory to making a key continuation decision under its 2014 collaboration agreement with Geron . Geron invest… read more...

Geron: Decision Next In Line

via: SeekingAlpha at 2018-08-03 10:57:42:000

Geron ( GERN ) is at a critical point in its 30 odd-year history. This quarter, the one the ends September 30, 2018, is the one that Geron has told its investors to expect a definitive decision by Johnson & Johnson ( JNJ ) subsidiary, Janssen, as to whether or not it will elect to continue… read more...

Geron: Decision Next In Line

via: SeekingAlpha at 2018-08-03 10:57:42:000

Geron ( GERN ) is at a critical point in its 30 odd-year history. This quarter, the one the ends September 30, 2018, is the one that Geron has told its investors to expect a definitive decision by Johnson & Johnson ( JNJ ) subsidiary, Janssen, as to whether or not it will elect to continue… read more...

Geron: Decision Next In Line

via: SeekingAlpha at 2018-08-03 10:57:42:000

Geron ( GERN ) is at a critical point in its 30 odd-year history. This quarter, the one the ends September 30, 2018, is the one that Geron has told its investors to expect a definitive decision by Johnson & Johnson ( JNJ ) subsidiary, Janssen, as to whether or not it will elect to continue… read more...

Geron: Decision Next In Line

via: SeekingAlpha at 2018-08-03 10:57:42:000

Geron ( GERN ) is at a critical point in its 30 odd-year history. This quarter, the one the ends September 30, 2018, is the one that Geron has told its investors to expect a definitive decision by Johnson & Johnson ( JNJ ) subsidiary, Janssen, as to whether or not it will elect to continue… read more...

Geron: Decision Next In Line

via: SeekingAlpha at 2018-08-03 10:57:42:000

Geron ( GERN ) is at a critical point in its 30 odd-year history. This quarter, the one the ends September 30, 2018, is the one that Geron has told its investors to expect a definitive decision by Johnson & Johnson ( JNJ ) subsidiary, Janssen, as to whether or not it will elect to continue… read more...

3 Things In Biotech, August 2: Japanese Drug Makers Rise And Fall

via: SeekingAlpha at 2018-08-02 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Otsuka failure portends termination of an important AML study Company: Otsuka ( OTCPK:O… read more...

Geron's (GERN) CEO Dr. John Scarlett on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-31 22:43:15:000

Geron Corporation (GERN) Q2 2018 Results Earnings Conference Call July 31, 2018, 4:30 PM ET Executives Suzanne Messere - Investor Relations Dr. John Scarlett - President and CEO Olivia Bloom - Chief Financial Officer Analysts George Zavoico - B. Riley FBR Michael Kay - Ka… read more...

After Hours Gainers / Losers (07/31/2018)

via: SeekingAlpha at 2018-07-31 17:36:32:000

Top Gainers: MOH +15.2% . PAYC +10.5%. TCS +10.1% . ZEN +6.9% . P +6.8% . More news on: Molina Healthcare, Inc., Paycom Software, Inc., The Container Store Group, Inc., Stocks on the move, , Read more … read more...

Geron reports Q2 results

via: SeekingAlpha at 2018-07-31 16:10:29:000

Geron (NASDAQ: GERN ): Q2 EPS of -$0.04 Revenue of $0.21M (+23.5% Y/Y) Press Release More news on: Geron Corporation, Earnings news and commentary, Healthcare stocks news, read more...

Geron Investors Are Looking For Some Answers At The Upcoming (Last?) Conference Call

via: SeekingAlpha at 2018-07-30 16:24:05:000

Source: PublicDomainPictures With only 60 days left until the deadline for Johnson & Johnson ( JNJ ) to make a continuation decision in their collaboration with Geron ( GERN ), investors have some question they'd like answered in GERN's Q2 conference call. What investors learn on t… read more...

Janssen's History And Continuation Decision With Imetelstat

via: SeekingAlpha at 2018-07-25 05:49:28:000

Background Janssen's pursuit of Imetelstat began in 2013. A confidentiality agreement was executed between Geron ( GERN ) and Janssen ( JNJ ) on October 31, 2013. Geron's formal relationship with Janssen began ~30 days after Geron divested their Stem Cell business, and ~1 week before the pub… read more...

Janssen's History And Continuation Decision With Imetelstat

via: SeekingAlpha at 2018-07-25 05:49:28:000

Background Janssen's pursuit of Imetelstat began in 2013. A confidentiality agreement was executed between Geron ( GERN ) and Janssen ( JNJ ) on October 31, 2013. Geron's formal relationship with Janssen began ~30 days after Geron divested their Stem Cell business, and ~1 week before the pub… read more...

Janssen's History And Continuation Decision With Imetelstat

via: SeekingAlpha at 2018-07-25 05:49:28:000

Background Janssen's pursuit of Imetelstat began in 2013. A confidentiality agreement was executed between Geron ( GERN ) and Janssen ( JNJ ) on October 31, 2013. Geron's formal relationship with Janssen began ~30 days after Geron divested their Stem Cell business, and ~1 week before the pub… read more...

Geron: Anticipation Building

via: SeekingAlpha at 2018-07-20 00:34:33:000

"We can never know about the days to come, b ut we think about them anyway." These are the first two lines of Carly Simon's finest song . They capture the essence of the focus that many Geron ( GERN ) investors have placed on the dwindling 73 days between now and September 30, 2018, when [[… read more...

Geron: Anticipation Building

via: SeekingAlpha at 2018-07-20 00:34:33:000

"We can never know about the days to come, b ut we think about them anyway." These are the first two lines of Carly Simon's finest song . They capture the essence of the focus that many Geron ( GERN ) investors have placed on the dwindling 73 days between now and September 30, 2018, when [[… read more...

Geron: Anticipation Building

via: SeekingAlpha at 2018-07-20 00:34:33:000

"We can never know about the days to come, b ut we think about them anyway." These are the first two lines of Carly Simon's finest song . They capture the essence of the focus that many Geron ( GERN ) investors have placed on the dwindling 73 days between now and September 30, 2018, when [[… read more...

Geron: Anticipation Building

via: SeekingAlpha at 2018-07-20 00:34:33:000

"We can never know about the days to come, b ut we think about them anyway." These are the first two lines of Carly Simon's finest song . They capture the essence of the focus that many Geron ( GERN ) investors have placed on the dwindling 73 days between now and September 30, 2018, when [[… read more...

Geron: Anticipation Building

via: SeekingAlpha at 2018-07-20 00:34:33:000

"We can never know about the days to come, b ut we think about them anyway." These are the first two lines of Carly Simon's finest song . They capture the essence of the focus that many Geron ( GERN ) investors have placed on the dwindling 73 days between now and September 30, 2018, when [[… read more...

Premarket Gainers as of 9:05 am (07/17/2018)

via: SeekingAlpha at 2018-07-17 09:14:00:000

AMRH +64% secured a project to implement a robotic process automation solution with MedData. More news on: Ameri Holdings, Inc., Cellectar Biosciences, Inc., New Concept Energy, Inc., Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am (07/17/2018)

via: SeekingAlpha at 2018-07-17 09:14:00:000

AMRH +64% secured a project to implement a robotic process automation solution with MedData. More news on: Ameri Holdings, Inc., Cellectar Biosciences, Inc., New Concept Energy, Inc., Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am (07/17/2018)

via: SeekingAlpha at 2018-07-17 09:14:00:000

AMRH +64% secured a project to implement a robotic process automation solution with MedData. More news on: Ameri Holdings, Inc., Cellectar Biosciences, Inc., New Concept Energy, Inc., Stocks on the move, Read more … read more...

Geron: Oasis Ahead

via: SeekingAlpha at 2018-07-11 18:06:05:000

Johnson and Johnson's ( JNJ ) subsidiary, Janssen, is on the verge of making a decision of critical moment to its collaboration partner Geron ( GERN ). The two companies are pursuing a collaboration agreement focused on the development of cancer therapy imetelstat. Geron has told investors… read more...

Geron: Oasis Ahead

via: SeekingAlpha at 2018-07-11 18:06:05:000

Johnson and Johnson's ( JNJ ) subsidiary, Janssen, is on the verge of making a decision of critical moment to its collaboration partner Geron ( GERN ). The two companies are pursuing a collaboration agreement focused on the development of cancer therapy imetelstat. Geron has told investors… read more...

Geron: Oasis Ahead

via: SeekingAlpha at 2018-07-11 18:06:05:000

Johnson and Johnson's ( JNJ ) subsidiary, Janssen, is on the verge of making a decision of critical moment to its collaboration partner Geron ( GERN ). The two companies are pursuing a collaboration agreement focused on the development of cancer therapy imetelstat. Geron has told investors… read more...

3 Things In Biotech, June 11: Acceleron's Second Punch, Advaxis's Letdown, Seattle's New Hope

via: SeekingAlpha at 2018-07-11 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Acceleron and Celgene land another big blow with their TGF blocker Company: Acceleron… read more...

3 Things In Biotech, June 11: Acceleron's Second Punch, Advaxis's Letdown, Seattle's New Hope

via: SeekingAlpha at 2018-07-11 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Acceleron and Celgene land another big blow with their TGF blocker Company: Acceleron… read more...

3 Things In Biotech, June 11: Acceleron's Second Punch, Advaxis's Letdown, Seattle's New Hope

via: SeekingAlpha at 2018-07-11 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Acceleron and Celgene land another big blow with their TGF blocker Company: Acceleron… read more...

Learn How To Invest Against Acute Myeloid Leukemia, One Of The Fastest-Growing Cancer Markets

via: SeekingAlpha at 2018-07-09 08:00:00:000

The most important weapon we as investors have in our arsenals is knowledge. Many of the people I've spoken with on Seeking Alpha and other forums have demonstrated keen awareness of the clinical pipeline for their company of interest. However, it is often difficult for them to place the resul… read more...

Learn How To Invest Against Acute Myeloid Leukemia, One Of The Fastest-Growing Cancer Markets

via: SeekingAlpha at 2018-07-09 08:00:00:000

The most important weapon we as investors have in our arsenals is knowledge. Many of the people I've spoken with on Seeking Alpha and other forums have demonstrated keen awareness of the clinical pipeline for their company of interest. However, it is often difficult for them to place the resul… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-07-05 08:55:16:000

Valeritas Holdings (NASDAQ: VLRX ) initiated with Outperform rating and $3.50 (159% upside) price target at Oppenheimer. Shares are up 15% premarket. More news on: Valeritas Holdings, Inc., Geron Corporation, Deciphera Pharmaceuticals, Inc., Healthcare stocks news, Stocks on th… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-07-05 08:55:16:000

Valeritas Holdings (NASDAQ: VLRX ) initiated with Outperform rating and $3.50 (159% upside) price target at Oppenheimer. Shares are up 15% premarket. More news on: Valeritas Holdings, Inc., Geron Corporation, Deciphera Pharmaceuticals, Inc., Healthcare stocks news, Stocks on th… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-07-05 08:55:16:000

Valeritas Holdings (NASDAQ: VLRX ) initiated with Outperform rating and $3.50 (159% upside) price target at Oppenheimer. Shares are up 15% premarket. More news on: Valeritas Holdings, Inc., Geron Corporation, Deciphera Pharmaceuticals, Inc., Healthcare stocks news, Stocks on th… read more...

3 Things In Biotech, July 1: Acceleron's Big Break, Astellas Solidifies, Cellectar Has A Chance?

via: SeekingAlpha at 2018-07-01 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Acceleron reaches for the gold in a pivotal trial Company: Acceleron ( XLRN ) and Celgene ( CELG ) Therapy: Lusp… read more...

3 Things In Biotech, July 1: Acceleron's Big Break, Astellas Solidifies, Cellectar Has A Chance?

via: SeekingAlpha at 2018-07-01 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Acceleron reaches for the gold in a pivotal trial Company: Acceleron ( XLRN ) and Celgene ( CELG ) Therapy: Lusp… read more...

3 Things In Biotech, July 1: Acceleron's Big Break, Astellas Solidifies, Cellectar Has A Chance?

via: SeekingAlpha at 2018-07-01 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Acceleron reaches for the gold in a pivotal trial Company: Acceleron ( XLRN ) and Celgene ( CELG ) Therapy: Lusp… read more...

A Closer Look At The Geron Janssen Collaboration Agreement

via: SeekingAlpha at 2018-06-29 08:31:33:000

Expectations, expectations. Decision time is expected soon in Geron-land. Geron ( GERN ) investors are expecting to learn this quarter (Q3, 2018) whether or not Johnson and Johnson ( JNJ ) subsidiary Janssen will exercise a continuation option under its 2014 collaboration agreement with Geron…. read more...

A Closer Look At The Geron Janssen Collaboration Agreement

via: SeekingAlpha at 2018-06-29 08:31:33:000

Expectations, expectations. Decision time is expected soon in Geron-land. Geron ( GERN ) investors are expecting to learn this quarter (Q3, 2018) whether or not Johnson and Johnson ( JNJ ) subsidiary Janssen will exercise a continuation option under its 2014 collaboration agreement with Geron…. read more...

Geron: What The Latest Data For IMerge Foretells?

via: SeekingAlpha at 2018-06-29 05:44:59:000

Youll do better if you have passion for something in which you have aptitude. If Warren Buffett had gone into ballet, no one would have heard of him. - Charlie Munger Geron Corporation (NASDAQ: GERN ) is a highly promising bioscience that is quite volatile. From what we observed … read more...

Geron: What The Latest Data For IMerge Foretells?

via: SeekingAlpha at 2018-06-29 05:44:59:000

Youll do better if you have passion for something in which you have aptitude. If Warren Buffett had gone into ballet, no one would have heard of him. - Charlie Munger Geron Corporation (NASDAQ: GERN ) is a highly promising bioscience that is quite volatile. From what we observed … read more...

Geron's EHA Data Begin To Paint A Clearer Picture. Is It For Good Or Ill?

via: SeekingAlpha at 2018-06-25 08:30:00:000

Note: Subscribers to the Total Pharma Tracker gain exclusive early access to my articles, as well as the ability to chat with me in real time about this and other writings. Geron Corp ( GERN ) has had just about every angle and every facet of its business and science scrutinized for… read more...

Geron's EHA Data Begin To Paint A Clearer Picture. Is It For Good Or Ill?

via: SeekingAlpha at 2018-06-25 08:30:00:000

Note: Subscribers to the Total Pharma Tracker gain exclusive early access to my articles, as well as the ability to chat with me in real time about this and other writings. Geron Corp ( GERN ) has had just about every angle and every facet of its business and science scrutinized for… read more...

Geron's EHA Data Begin To Paint A Clearer Picture. Is It For Good Or Ill?

via: SeekingAlpha at 2018-06-25 08:30:00:000

Note: Subscribers to the Total Pharma Tracker gain exclusive early access to my articles, as well as the ability to chat with me in real time about this and other writings. Geron Corp ( GERN ) has had just about every angle and every facet of its business and science scrutinized for… read more...

Asterias Biotherapeutics: A Game Changer For Cervical Spinal Cord Injuries And Cancer

via: SeekingAlpha at 2018-06-22 14:51:31:000

Introduction to Company While we tend to not cover such small companies with early pipeline candidates, Asterias Biotherapeutics ( AST ) has definitely piqued our interest. AST is a micro-cap biotechnology company with a focus on tackling two very different issues: cervical spinal cord inj… read more...

Asterias Biotherapeutics: A Game Changer For Cervical Spinal Cord Injuries And Cancer

via: SeekingAlpha at 2018-06-22 14:51:31:000

Introduction to Company While we tend to not cover such small companies with early pipeline candidates, Asterias Biotherapeutics ( AST ) has definitely piqued our interest. AST is a micro-cap biotechnology company with a focus on tackling two very different issues: cervical spinal cord inj… read more...

Asterias Biotherapeutics: A Game Changer For Cervical Spinal Cord Injuries And Cancer

via: SeekingAlpha at 2018-06-22 14:51:31:000

Introduction to Company While we tend to not cover such small companies with early pipeline candidates, Asterias Biotherapeutics ( AST ) has definitely piqued our interest. AST is a micro-cap biotechnology company with a focus on tackling two very different issues: cervical spinal cord inj… read more...

3 Things In Biotech, June 19: Geron Just Can't Win, Verastem Breaks Out

via: SeekingAlpha at 2018-06-20 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription ? Welcome to another edition of "3 Things In Biotech You Should Learn Today," … read more...

3 Things In Biotech, June 19: Geron Just Can't Win, Verastem Breaks Out

via: SeekingAlpha at 2018-06-20 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription ? Welcome to another edition of "3 Things In Biotech You Should Learn Today," … read more...

Your Daily Pharma Scoop: TG Therapeutics Phase 2 Results, Geron Positive, Agio In Phase 3

via: SeekingAlpha at 2018-06-20 08:00:00:000

Analysis Focus: TGTX TG Therapeutics ( TGTX ) announced preliminary data from the Phase 2 clinical trial of its lead candidate umbralisib (TGR-1202) in patients with relapsed/refractory chronic lymphocytic leukemia or r/r CLL, who were intolerant to prior BTK or PI3K therapy. The data that… read more...

Your Daily Pharma Scoop: TG Therapeutics Phase 2 Results, Geron Positive, Agio In Phase 3

via: SeekingAlpha at 2018-06-20 08:00:00:000

Analysis Focus: TGTX TG Therapeutics ( TGTX ) announced preliminary data from the Phase 2 clinical trial of its lead candidate umbralisib (TGR-1202) in patients with relapsed/refractory chronic lymphocytic leukemia or r/r CLL, who were intolerant to prior BTK or PI3K therapy. The data that… read more...

Premarket Gainers as of 9:05 am (06/18/2018)

via: SeekingAlpha at 2018-06-18 09:28:06:000

PTCT +33% on positive analyst action. More news on: PTC Therapeutics, China Biologic Products, Inc., Gevo, Inc., Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am (06/18/2018)

via: SeekingAlpha at 2018-06-18 09:28:06:000

PTCT +33% on positive analyst action. More news on: PTC Therapeutics, China Biologic Products, Inc., Gevo, Inc., Stocks on the move, Read more … read more...

3 Things In Biotech, June 17: Ruxolitinib Climbs Higher

via: SeekingAlpha at 2018-06-18 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription? Welcome to another edition of "3 Things In Biotech," a daily digest dedicate… read more...

3 Things In Biotech, June 17: Ruxolitinib Climbs Higher

via: SeekingAlpha at 2018-06-18 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription? Welcome to another edition of "3 Things In Biotech," a daily digest dedicate… read more...

Geron shows positive effect in Phase 2/3 MDS study; shares up 5% premarket

via: SeekingAlpha at 2018-06-18 07:28:13:000

Geron (NASDAQ: GERN ) is up 5% premarket on light volume in response to its announcement of positive results from a Phase 2/3 clinical trial, iMerge, evaluating imetelstat in lower-risk myelodysplastic syndromes (MDS). The data were presented at EHA in Stockholm. More news on… read more...

Geron shows positive effect in Phase 2/3 MDS study; shares up 5% premarket

via: SeekingAlpha at 2018-06-18 07:28:13:000

Geron (NASDAQ: GERN ) is up 5% premarket on light volume in response to its announcement of positive results from a Phase 2/3 clinical trial, iMerge, evaluating imetelstat in lower-risk myelodysplastic syndromes (MDS). The data were presented at EHA in Stockholm. More news on… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-08 07:35:23:000

Noteworthy events during the week of June 10 - 16 for healthcare investors. More news on: Avenue Therapeutics, Cardinal Health Inc., La Jolla Pharmaceutical Co., Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-08 07:35:23:000

Noteworthy events during the week of June 10 - 16 for healthcare investors. More news on: Avenue Therapeutics, Cardinal Health Inc., La Jolla Pharmaceutical Co., Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-08 07:35:23:000

Noteworthy events during the week of June 10 - 16 for healthcare investors. More news on: Avenue Therapeutics, Cardinal Health Inc., La Jolla Pharmaceutical Co., Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-08 07:35:23:000

Noteworthy events during the week of June 10 - 16 for healthcare investors. More news on: Avenue Therapeutics, Cardinal Health Inc., La Jolla Pharmaceutical Co., Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-08 07:35:23:000

Noteworthy events during the week of June 10 - 16 for healthcare investors. More news on: Avenue Therapeutics, Cardinal Health Inc., La Jolla Pharmaceutical Co., Healthcare stocks news, , Read more … read more...

Crispr Therapeutics: What The FDA Clinical Hold On CTX-001 For Sickle Cell Disease Entails

via: SeekingAlpha at 2018-06-08 02:25:25:000

The true investor scarcely ever is forced to sell his shares, and at all other times he is free to disregard the current price quotation. He need pay attention to it and act upon it only to the extent that it suits his book, and no more. Thus the investor who permits himself to be stamp… read more...

Crispr Therapeutics: What The FDA Clinical Hold On CTX-001 For Sickle Cell Disease Entails

via: SeekingAlpha at 2018-06-08 02:25:25:000

The true investor scarcely ever is forced to sell his shares, and at all other times he is free to disregard the current price quotation. He need pay attention to it and act upon it only to the extent that it suits his book, and no more. Thus the investor who permits himself to be stamp… read more...

Crispr Therapeutics: What The FDA Clinical Hold On CTX-001 For Sickle Cell Disease Entails

via: SeekingAlpha at 2018-06-08 02:25:25:000

The true investor scarcely ever is forced to sell his shares, and at all other times he is free to disregard the current price quotation. He need pay attention to it and act upon it only to the extent that it suits his book, and no more. Thus the investor who permits himself to be stamp… read more...

Crispr Therapeutics: What The FDA Clinical Hold On CTX-001 For Sickle Cell Disease Entails

via: SeekingAlpha at 2018-06-08 02:25:25:000

The true investor scarcely ever is forced to sell his shares, and at all other times he is free to disregard the current price quotation. He need pay attention to it and act upon it only to the extent that it suits his book, and no more. Thus the investor who permits himself to be stamp… read more...

Crispr Therapeutics: What The FDA Clinical Hold On CTX-001 For Sickle Cell Disease Entails

via: SeekingAlpha at 2018-06-08 02:25:25:000

The true investor scarcely ever is forced to sell his shares, and at all other times he is free to disregard the current price quotation. He need pay attention to it and act upon it only to the extent that it suits his book, and no more. Thus the investor who permits himself to be stamp… read more...

Redux: My 3 January Effect Candidates Are Producing Major Alpha Through May

via: SeekingAlpha at 2018-05-30 13:51:36:000

Back in early January my article "3 Biotechs For The January Effect" was published. The article highlighted Geron ( GERN ), Antares Pharma ( ATRS ) and AcelRX ( ACRX ). This article is to assess my picks so far in May and outline prospects going forward to determine if we should sell, hold… read more...

Redux: My 3 January Effect Candidates Are Producing Major Alpha Through May

via: SeekingAlpha at 2018-05-30 13:51:36:000

Back in early January my article "3 Biotechs For The January Effect" was published. The article highlighted Geron ( GERN ), Antares Pharma ( ATRS ) and AcelRX ( ACRX ). This article is to assess my picks so far in May and outline prospects going forward to determine if we should sell, hold… read more...

Redux: My 3 January Effect Candidates Are Producing Major Alpha Through May

via: SeekingAlpha at 2018-05-30 13:51:36:000

Back in early January my article "3 Biotechs For The January Effect" was published. The article highlighted Geron ( GERN ), Antares Pharma ( ATRS ) and AcelRX ( ACRX ). This article is to assess my picks so far in May and outline prospects going forward to determine if we should sell, hold… read more...

Premarket Losers as of 9:05 am (5/25/2018)

via: SeekingAlpha at 2018-05-25 09:16:46:000

ZOES -29% on Q1 earnings . More news on: Zoe's Kitchen, Rockwell Medical, Inc., BG Staffing Inc, Stocks on the move, , Read more … read more...

Premarket Losers as of 9:05 am (5/25/2018)

via: SeekingAlpha at 2018-05-25 09:16:46:000

ZOES -29% on Q1 earnings . More news on: Zoe's Kitchen, Rockwell Medical, Inc., BG Staffing Inc, Stocks on the move, , Read more … read more...

Premarket Losers as of 9:05 am (5/25/2018)

via: SeekingAlpha at 2018-05-25 09:16:46:000

ZOES -29% on Q1 earnings . More news on: Zoe's Kitchen, Rockwell Medical, Inc., BG Staffing Inc, Stocks on the move, , Read more … read more...

Premarket Losers as of 9:05 am (5/25/2018)

via: SeekingAlpha at 2018-05-25 09:16:46:000

ZOES -29% on Q1 earnings . More news on: Zoe's Kitchen, Rockwell Medical, Inc., BG Staffing Inc, Stocks on the move, , Read more … read more...

Premarket Losers as of 9:05 am (5/25/2018)

via: SeekingAlpha at 2018-05-25 09:16:46:000

ZOES -29% on Q1 earnings . More news on: Zoe's Kitchen, Rockwell Medical, Inc., BG Staffing Inc, Stocks on the move, , Read more … read more...

Premarket Losers as of 9:05 am (5/25/2018)

via: SeekingAlpha at 2018-05-25 09:16:46:000

ZOES -29% on Q1 earnings . More news on: Zoe's Kitchen, Rockwell Medical, Inc., BG Staffing Inc, Stocks on the move, , Read more … read more...

Geron: Beware Shorts Slinging Bull (Longs Do It Too)

via: SeekingAlpha at 2018-05-25 08:36:15:000

The Geron ( GERN ) story can be, and for sanity's sake is best kept, simple at the current time. Just the essential facts are all that is necessary now. I will suggest how newcomers might approach the stock. At the close of the article I briefly discuss today's (5/24/18) SEC filing . Geron'… read more...

Geron: Beware Shorts Slinging Bull (Longs Do It Too)

via: SeekingAlpha at 2018-05-25 08:36:15:000

The Geron ( GERN ) story can be, and for sanity's sake is best kept, simple at the current time. Just the essential facts are all that is necessary now. I will suggest how newcomers might approach the stock. At the close of the article I briefly discuss today's (5/24/18) SEC filing . Geron'… read more...

Geron: Beware Shorts Slinging Bull (Longs Do It Too)

via: SeekingAlpha at 2018-05-25 08:36:15:000

The Geron ( GERN ) story can be, and for sanity's sake is best kept, simple at the current time. Just the essential facts are all that is necessary now. I will suggest how newcomers might approach the stock. At the close of the article I briefly discuss today's (5/24/18) SEC filing . Geron'… read more...

Geron: Beware Shorts Slinging Bull (Longs Do It Too)

via: SeekingAlpha at 2018-05-25 08:36:15:000

The Geron ( GERN ) story can be, and for sanity's sake is best kept, simple at the current time. Just the essential facts are all that is necessary now. I will suggest how newcomers might approach the stock. At the close of the article I briefly discuss today's (5/24/18) SEC filing . Geron'… read more...

Geron: Beware Shorts Slinging Bull (Longs Do It Too)

via: SeekingAlpha at 2018-05-25 08:36:15:000

The Geron ( GERN ) story can be, and for sanity's sake is best kept, simple at the current time. Just the essential facts are all that is necessary now. I will suggest how newcomers might approach the stock. At the close of the article I briefly discuss today's (5/24/18) SEC filing . Geron'… read more...

Geron: Beware Shorts Slinging Bull (Longs Do It Too)

via: SeekingAlpha at 2018-05-25 08:36:15:000

The Geron ( GERN ) story can be, and for sanity's sake is best kept, simple at the current time. Just the essential facts are all that is necessary now. I will suggest how newcomers might approach the stock. At the close of the article I briefly discuss today's (5/24/18) SEC filing . Geron'… read more...

After Hours Gainers / Losers (05/24/2018)

via: SeekingAlpha at 2018-05-24 17:38:02:000

Gainers: CAVM +6.1% . DECK +4.1% . NWY +3.9% . AMRN +3.8% . MRVL +2.1% . More news on: Cavium Networks, Inc., Deckers Outdoor Corporation, New York & Company, Inc., Stocks on the move, , News on ETFs, Read more … read more...

After Hours Gainers / Losers (05/24/2018)

via: SeekingAlpha at 2018-05-24 17:38:02:000

Gainers: CAVM +6.1% . DECK +4.1% . NWY +3.9% . AMRN +3.8% . MRVL +2.1% . More news on: Cavium Networks, Inc., Deckers Outdoor Corporation, New York & Company, Inc., Stocks on the move, , News on ETFs, Read more … read more...

After Hours Gainers / Losers (05/24/2018)

via: SeekingAlpha at 2018-05-24 17:38:02:000

Gainers: CAVM +6.1% . DECK +4.1% . NWY +3.9% . AMRN +3.8% . MRVL +2.1% . More news on: Cavium Networks, Inc., Deckers Outdoor Corporation, New York & Company, Inc., Stocks on the move, , News on ETFs, Read more … read more...

Midday Gainers / Losers (05/22/2018)

via: SeekingAlpha at 2018-05-22 12:41:50:000

Gainers: CPAH +16% . CRMT +15% . MDXG +13% . NSTG +12% . SDR +12% . FWP +11% . ARQL +11% . GERN +11% . SMRT +11% . AVEO +10% . More news on: CounterPath Corporation, America's Car-Mart, Inc., MiMedx Group Inc., Stocks on the move, , Read more … read more...

Midday Gainers / Losers (05/22/2018)

via: SeekingAlpha at 2018-05-22 12:41:50:000

Gainers: CPAH +16% . CRMT +15% . MDXG +13% . NSTG +12% . SDR +12% . FWP +11% . ARQL +11% . GERN +11% . SMRT +11% . AVEO +10% . More news on: CounterPath Corporation, America's Car-Mart, Inc., MiMedx Group Inc., Stocks on the move, , Read more … read more...

Midday Gainers / Losers (05/22/2018)

via: SeekingAlpha at 2018-05-22 12:41:50:000

Gainers: CPAH +16% . CRMT +15% . MDXG +13% . NSTG +12% . SDR +12% . FWP +11% . ARQL +11% . GERN +11% . SMRT +11% . AVEO +10% . More news on: CounterPath Corporation, America's Car-Mart, Inc., MiMedx Group Inc., Stocks on the move, , Read more … read more...

Making The Bull Case For Geron: Understanding The Risk/Reward Of Telomerase Biology

via: SeekingAlpha at 2018-05-18 08:45:16:000

Editor's note: Seeking Alpha is proud to welcome Delmar Price as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Many investo… read more...

Making The Bull Case For Geron: Understanding The Risk/Reward Of Telomerase Biology

via: SeekingAlpha at 2018-05-18 08:45:16:000

Editor's note: Seeking Alpha is proud to welcome Delmar Price as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Many investo… read more...

Making The Bull Case For Geron: Understanding The Risk/Reward Of Telomerase Biology

via: SeekingAlpha at 2018-05-18 08:45:16:000

Editor's note: Seeking Alpha is proud to welcome Delmar Price as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Many investo… read more...

Making The Bull Case For Geron: Understanding The Risk/Reward Of Telomerase Biology

via: SeekingAlpha at 2018-05-18 08:45:16:000

Editor's note: Seeking Alpha is proud to welcome Delmar Price as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Many investo… read more...

Making The Bull Case For Geron: Understanding The Risk/Reward Of Telomerase Biology

via: SeekingAlpha at 2018-05-18 08:45:16:000

Editor's note: Seeking Alpha is proud to welcome Delmar Price as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Many investo… read more...

Making The Bull Case For Geron: Understanding The Risk/Reward Of Telomerase Biology

via: SeekingAlpha at 2018-05-18 08:45:16:000

Editor's note: Seeking Alpha is proud to welcome Delmar Price as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Many investo… read more...

Making The Bull Case For Geron: Understanding The Risk/Reward Of Telomerase Biology

via: SeekingAlpha at 2018-05-18 08:45:16:000

Editor's note: Seeking Alpha is proud to welcome Delmar Price as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Many investo… read more...

Making The Bull Case For Geron: Understanding The Risk/Reward Of Telomerase Biology

via: SeekingAlpha at 2018-05-18 08:45:16:000

Editor's note: Seeking Alpha is proud to welcome Delmar Price as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Many investo… read more...

Making The Bull Case For Geron: Understanding The Risk/Reward Of Telomerase Biology

via: SeekingAlpha at 2018-05-18 08:45:16:000

Editor's note: Seeking Alpha is proud to welcome Delmar Price as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Many investo… read more...

Making The Bull Case For Geron: Understanding The Risk/Reward Of Telomerase Biology

via: SeekingAlpha at 2018-05-18 08:45:16:000

Editor's note: Seeking Alpha is proud to welcome Delmar Price as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Many investo… read more...

Making The Bull Case For Geron: Understanding The Risk/Reward Of Telomerase Biology

via: SeekingAlpha at 2018-05-18 08:45:16:000

Editor's note: Seeking Alpha is proud to welcome Delmar Price as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Many investo… read more...

Geron down 8% premarket after Q1 report

via: SeekingAlpha at 2018-05-11 08:20:40:000

Geron (NASDAQ: GERN ) Q1 results ($M): Revenues from licence fees & royalties: 0.3 (-40.8%); Net loss: (7.2) (flat). More news on: Geron Corporation, Healthcare stocks news, Stocks on the move, Earnings news and commentary, Read more … read more...

Geron down 8% premarket after Q1 report

via: SeekingAlpha at 2018-05-11 08:20:40:000

Geron (NASDAQ: GERN ) Q1 results ($M): Revenues from licence fees & royalties: 0.3 (-40.8%); Net loss: (7.2) (flat). More news on: Geron Corporation, Healthcare stocks news, Stocks on the move, Earnings news and commentary, Read more … read more...

Geron beats by $0.01

via: SeekingAlpha at 2018-05-10 16:16:17:000

Geron (NASDAQ: GERN ): Q1 EPS of -$0.04 beats by $0.01 . Revenue of $0.32M (-40.7% Y/Y) Shares +1.9% . Press Release More news on: Geron Corporation, Earnings news and commentary, Stocks on the move, Healthcare stocks news, read more...

Geron beats by $0.01

via: SeekingAlpha at 2018-05-10 16:16:17:000

Geron (NASDAQ: GERN ): Q1 EPS of -$0.04 beats by $0.01 . Revenue of $0.32M (-40.7% Y/Y) Shares +1.9% . Press Release More news on: Geron Corporation, Earnings news and commentary, Stocks on the move, Healthcare stocks news, read more...

The No BS Report, Week 12: Living In Yawnsville With Little But Gains

via: SeekingAlpha at 2018-05-06 08:58:28:000

Author's note: As always, I'm happy to answer questions in the comments below, but you can get direct access to me in the Total Pharma Tracker chatroom if you want to discuss in further detail! Right now you can get a no-obligation free trial to the service for two weeks. Welcome to an… read more...

The No BS Report, Week 12: Living In Yawnsville With Little But Gains

via: SeekingAlpha at 2018-05-06 08:58:28:000

Author's note: As always, I'm happy to answer questions in the comments below, but you can get direct access to me in the Total Pharma Tracker chatroom if you want to discuss in further detail! Right now you can get a no-obligation free trial to the service for two weeks. Welcome to an… read more...

Liking Box Since $12 - Cramer's Lightning Round (5/1/18)

via: SeekingAlpha at 2018-05-02 06:42:10:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, May 1. Bullish Calls Box (BOX): Cramer has liked the stock since $12. CEO Aaron Levie is good. Applied Materials (AMAT): "I know a lot of people are selling Applied Materials because they feel l… read more...

Liking Box Since $12 - Cramer's Lightning Round (5/1/18)

via: SeekingAlpha at 2018-05-02 06:42:10:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, May 1. Bullish Calls Box (BOX): Cramer has liked the stock since $12. CEO Aaron Levie is good. Applied Materials (AMAT): "I know a lot of people are selling Applied Materials because they feel l… read more...

Cramer's lightning round: Get out of Hi-Crush before you get crushed

via: CNBC at 2018-05-01 18:47:00:000

No summary available. read more...

Cramer's lightning round: Get out of Hi-Crush before you get crushed

via: CNBC at 2018-05-01 18:47:00:000

No summary available. read more...

It's Illogical To Think That Johnson & Johnson Has Dropped Geron

via: SeekingAlpha at 2018-05-01 16:12:47:000

Background Story Imetelstat, a first-in-class telomerase inhibitor and Geron's sole product candidate, is currently in phase 2 (IMbark) and phase 2/3 (IMerge) clinical trials. Ever since Geron and JNJ announced a joint collaboration agreement in November 2014 to develop and commerciali… read more...

It's Illogical To Think That Johnson & Johnson Has Dropped Geron

via: SeekingAlpha at 2018-05-01 16:12:47:000

Background Story Imetelstat, a first-in-class telomerase inhibitor and Geron's sole product candidate, is currently in phase 2 (IMbark) and phase 2/3 (IMerge) clinical trials. Ever since Geron and JNJ announced a joint collaboration agreement in November 2014 to develop and commerciali… read more...

Geron Bear V. Bull - 50¢ Or $50

via: SeekingAlpha at 2018-05-01 00:05:07:000

Geron ( GERN ) is a tiny biotech, <$1 billion market cap, with an oversized history and an undersized pipeline. Its CEO has managed to steer the company through the wilderness within clear sight of the promised land. He expects that by Q3 2018, Johnson & Johnson's ( JNJ ) subsidia… read more...

Geron Bear V. Bull - 50¢ Or $50

via: SeekingAlpha at 2018-05-01 00:05:07:000

Geron ( GERN ) is a tiny biotech, <$1 billion market cap, with an oversized history and an undersized pipeline. Its CEO has managed to steer the company through the wilderness within clear sight of the promised land. He expects that by Q3 2018, Johnson & Johnson's ( JNJ ) subsidia… read more...

The No BS Report, Week 11: Rising Tides And Sinking Ships?

via: SeekingAlpha at 2018-04-29 14:04:14:000

Author's note: As always, I'm happy to answer questions in the comments below, but you can get direct access to me in the Total Pharma Tracker chatroom if you want to discuss in further detail! Right now you can get a no-obligation free trial to the service for two weeks. Welcome to an… read more...

The No BS Report, Week 11: Rising Tides And Sinking Ships?

via: SeekingAlpha at 2018-04-29 14:04:14:000

Author's note: As always, I'm happy to answer questions in the comments below, but you can get direct access to me in the Total Pharma Tracker chatroom if you want to discuss in further detail! Right now you can get a no-obligation free trial to the service for two weeks. Welcome to an… read more...

We Believe Janssen Has Separated From Geron. Just Awaiting Divorce Papers

via: SeekingAlpha at 2018-04-26 08:30:00:000

Janssen has removed or omitted imetelstat from key presentation materials We believe Geron (GERN) bulls are missing a key piece of evidence that suggests to us that Janssen (JNJ) is likely to terminate its licensing agreement for imetelstat. In every Johnson & Johnson (Janssen&#x2019… read more...

We Believe Janssen Has Separated From Geron. Just Awaiting Divorce Papers

via: SeekingAlpha at 2018-04-26 08:30:00:000

Janssen has removed or omitted imetelstat from key presentation materials We believe Geron (GERN) bulls are missing a key piece of evidence that suggests to us that Janssen (JNJ) is likely to terminate its licensing agreement for imetelstat. In every Johnson & Johnson (Janssen&#x2019… read more...

Don't Be Surprised When Johnson & Johnson Acquires Geron Within A Year

via: SeekingAlpha at 2018-04-25 12:18:00:000

The Rumor Mill Rumors of a buyout for Geron (NASDAQ: GERN ) have been around for a couple years now, but in the last several months the topic of a buyout has become a hot topic for many Geron investors. Last week I presented a logical argument why GERN is a great investment in terms of… read more...

Don't Be Surprised When Johnson & Johnson Acquires Geron Within A Year

via: SeekingAlpha at 2018-04-25 12:18:00:000

The Rumor Mill Rumors of a buyout for Geron (NASDAQ: GERN ) have been around for a couple years now, but in the last several months the topic of a buyout has become a hot topic for many Geron investors. Last week I presented a logical argument why GERN is a great investment in terms of… read more...

Geron: The Good, The Bad And The Ugly

via: SeekingAlpha at 2018-02-14 15:00:52:000

Geron ( GERN ) has been a yo-yo stock for a long time. It is not the Lone Ranger among its small cap biotech peers in this boom or bust market sector. However, it is a particularly stark example; Geron is about as close to a one-trick pony as you can find. Its one trick, imetelstat, has the … read more...

Geron: The Good, The Bad And The Ugly

via: SeekingAlpha at 2018-02-14 15:00:52:000

Geron ( GERN ) has been a yo-yo stock for a long time. It is not the Lone Ranger among its small cap biotech peers in this boom or bust market sector. However, it is a particularly stark example; Geron is about as close to a one-trick pony as you can find. Its one trick, imetelstat, has the … read more...

Geron: The Good, The Bad And The Ugly

via: SeekingAlpha at 2018-02-14 15:00:52:000

Geron ( GERN ) has been a yo-yo stock for a long time. It is not the Lone Ranger among its small cap biotech peers in this boom or bust market sector. However, it is a particularly stark example; Geron is about as close to a one-trick pony as you can find. Its one trick, imetelstat, has the … read more...

Geron: The Good, The Bad And The Ugly

via: SeekingAlpha at 2018-02-14 15:00:52:000

Geron ( GERN ) has been a yo-yo stock for a long time. It is not the Lone Ranger among its small cap biotech peers in this boom or bust market sector. However, it is a particularly stark example; Geron is about as close to a one-trick pony as you can find. Its one trick, imetelstat, has the … read more...

Geron: The Good, The Bad And The Ugly

via: SeekingAlpha at 2018-02-14 15:00:52:000

Geron ( GERN ) has been a yo-yo stock for a long time. It is not the Lone Ranger among its small cap biotech peers in this boom or bust market sector. However, it is a particularly stark example; Geron is about as close to a one-trick pony as you can find. Its one trick, imetelstat, has the … read more...

Geron: The Good, The Bad And The Ugly

via: SeekingAlpha at 2018-02-14 15:00:52:000

Geron ( GERN ) has been a yo-yo stock for a long time. It is not the Lone Ranger among its small cap biotech peers in this boom or bust market sector. However, it is a particularly stark example; Geron is about as close to a one-trick pony as you can find. Its one trick, imetelstat, has the … read more...

Geron: The Good, The Bad And The Ugly

via: SeekingAlpha at 2018-02-14 15:00:52:000

Geron ( GERN ) has been a yo-yo stock for a long time. It is not the Lone Ranger among its small cap biotech peers in this boom or bust market sector. However, it is a particularly stark example; Geron is about as close to a one-trick pony as you can find. Its one trick, imetelstat, has the … read more...

It May Never Be Celgene, But It's A Mistake To Discount Geron

via: SeekingAlpha at 2018-02-14 11:59:32:000

Analysts and shareholders look forward with bated breath to the prospects of Geron Corp ( GERN ), and in particular a pair of articles came out recently evaluating the long-term prospects of this company. And they couldnt be further apart in their conclusions. The first, MedTechBio&#… read more...

It May Never Be Celgene, But It's A Mistake To Discount Geron

via: SeekingAlpha at 2018-02-14 11:59:32:000

Analysts and shareholders look forward with bated breath to the prospects of Geron Corp ( GERN ), and in particular a pair of articles came out recently evaluating the long-term prospects of this company. And they couldnt be further apart in their conclusions. The first, MedTechBio&#… read more...

It May Never Be Celgene, But It's A Mistake To Discount Geron

via: SeekingAlpha at 2018-02-14 11:59:32:000

Analysts and shareholders look forward with bated breath to the prospects of Geron Corp ( GERN ), and in particular a pair of articles came out recently evaluating the long-term prospects of this company. And they couldnt be further apart in their conclusions. The first, MedTechBio&#… read more...

It May Never Be Celgene, But It's A Mistake To Discount Geron

via: SeekingAlpha at 2018-02-14 11:59:32:000

Analysts and shareholders look forward with bated breath to the prospects of Geron Corp ( GERN ), and in particular a pair of articles came out recently evaluating the long-term prospects of this company. And they couldnt be further apart in their conclusions. The first, MedTechBio&#… read more...

It May Never Be Celgene, But It's A Mistake To Discount Geron

via: SeekingAlpha at 2018-02-14 11:59:32:000

Analysts and shareholders look forward with bated breath to the prospects of Geron Corp ( GERN ), and in particular a pair of articles came out recently evaluating the long-term prospects of this company. And they couldnt be further apart in their conclusions. The first, MedTechBio&#… read more...

It May Never Be Celgene, But It's A Mistake To Discount Geron

via: SeekingAlpha at 2018-02-14 11:59:32:000

Analysts and shareholders look forward with bated breath to the prospects of Geron Corp ( GERN ), and in particular a pair of articles came out recently evaluating the long-term prospects of this company. And they couldnt be further apart in their conclusions. The first, MedTechBio&#… read more...

It May Never Be Celgene, But It's A Mistake To Discount Geron

via: SeekingAlpha at 2018-02-14 11:59:32:000

Analysts and shareholders look forward with bated breath to the prospects of Geron Corp ( GERN ), and in particular a pair of articles came out recently evaluating the long-term prospects of this company. And they couldnt be further apart in their conclusions. The first, MedTechBio&#… read more...

In This Stock Market, It's Time To Declare War On Biotech Bagholding

via: SeekingAlpha at 2018-02-12 00:21:41:000

Disclaimer: This article starts an experiment. I am not trying to sell you a method, and I make no guarantees as to its efficacy. It's simply an attempt to form a structure that investors in biotech can carry into other areas of investing, with tools built in to track performance and see w… read more...

In This Stock Market, It's Time To Declare War On Biotech Bagholding

via: SeekingAlpha at 2018-02-12 00:21:41:000

Disclaimer: This article starts an experiment. I am not trying to sell you a method, and I make no guarantees as to its efficacy. It's simply an attempt to form a structure that investors in biotech can carry into other areas of investing, with tools built in to track performance and see w… read more...

In This Stock Market, It's Time To Declare War On Biotech Bagholding

via: SeekingAlpha at 2018-02-12 00:21:41:000

Disclaimer: This article starts an experiment. I am not trying to sell you a method, and I make no guarantees as to its efficacy. It's simply an attempt to form a structure that investors in biotech can carry into other areas of investing, with tools built in to track performance and see w… read more...

Geron: Imetelstat's History Of Deaths And Safety Issues

via: SeekingAlpha at 2018-02-09 09:45:22:000

Investors seem to have gotten excited again about the prospects for Gerons ( GERN ) imetelstat, pushing the shares +50% year to date at its peak to nearly 9 month highs. We think new investors to Geron may be shocked to learn about what we see as imetelstats history of failed… read more...

Geron: Imetelstat's History Of Deaths And Safety Issues

via: SeekingAlpha at 2018-02-09 09:45:22:000

Investors seem to have gotten excited again about the prospects for Gerons ( GERN ) imetelstat, pushing the shares +50% year to date at its peak to nearly 9 month highs. We think new investors to Geron may be shocked to learn about what we see as imetelstats history of failed… read more...

Geron: Imetelstat's History Of Deaths And Safety Issues

via: SeekingAlpha at 2018-02-09 09:45:22:000

Investors seem to have gotten excited again about the prospects for Gerons ( GERN ) imetelstat, pushing the shares +50% year to date at its peak to nearly 9 month highs. We think new investors to Geron may be shocked to learn about what we see as imetelstats history of failed… read more...

Geron: Imetelstat's History Of Deaths And Safety Issues

via: SeekingAlpha at 2018-02-09 09:45:22:000

Investors seem to have gotten excited again about the prospects for Gerons ( GERN ) imetelstat, pushing the shares +50% year to date at its peak to nearly 9 month highs. We think new investors to Geron may be shocked to learn about what we see as imetelstats history of failed… read more...

Geron: Imetelstat's History Of Deaths And Safety Issues

via: SeekingAlpha at 2018-02-09 09:45:22:000

Investors seem to have gotten excited again about the prospects for Gerons ( GERN ) imetelstat, pushing the shares +50% year to date at its peak to nearly 9 month highs. We think new investors to Geron may be shocked to learn about what we see as imetelstats history of failed… read more...

Week 6 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-02-05 05:00:11:000

Breakout Forecast Selections for Week 6: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. I continue to … read more...

Week 6 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-02-05 05:00:11:000

Breakout Forecast Selections for Week 6: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. I continue to … read more...

Week 6 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-02-05 05:00:11:000

Breakout Forecast Selections for Week 6: This week I have selected two of the 8 breakout stocks to share from the subscription Breakout Portfolio. Healthcare biotechnology and technology stocks were the largest representation of breakout stocks in my screener for this week. I continue to … read more...

Midday Gainers / Losers (1/30/2018)

via: SeekingAlpha at 2018-01-30 12:41:17:000

Gainers: IMMY +20% . GERN +17% . TRNS +14% . AKAO +13% . AQ +12% . BBRG +12% . CO +11% . LMFA +11% . EXTR +11% . CBAY +10% . More news on: Imprimis Pharmaceuticals, Inc., Geron Corporation, Transcat, Inc., Stocks on the move, Read more … read more...

Midday Gainers / Losers (1/30/2018)

via: SeekingAlpha at 2018-01-30 12:41:17:000

Gainers: IMMY +20% . GERN +17% . TRNS +14% . AKAO +13% . AQ +12% . BBRG +12% . CO +11% . LMFA +11% . EXTR +11% . CBAY +10% . More news on: Imprimis Pharmaceuticals, Inc., Geron Corporation, Transcat, Inc., Stocks on the move, Read more … read more...

Midday Gainers / Losers (1/30/2018)

via: SeekingAlpha at 2018-01-30 12:41:17:000

Gainers: IMMY +20% . GERN +17% . TRNS +14% . AKAO +13% . AQ +12% . BBRG +12% . CO +11% . LMFA +11% . EXTR +11% . CBAY +10% . More news on: Imprimis Pharmaceuticals, Inc., Geron Corporation, Transcat, Inc., Stocks on the move, Read more … read more...

Geron continues rally, up 15%

via: SeekingAlpha at 2018-01-30 12:38:18:000

Micro cap Geron ( GERN +14.5% ) is up again today on a 5x surge in volume. Shares have rallied ~ 35% in two days. More news on: Geron Corporation, Healthcare stocks news, Stocks on the move, Read more … read more...

Geron continues rally, up 15%

via: SeekingAlpha at 2018-01-30 12:38:18:000

Micro cap Geron ( GERN +14.5% ) is up again today on a 5x surge in volume. Shares have rallied ~ 35% in two days. More news on: Geron Corporation, Healthcare stocks news, Stocks on the move, Read more … read more...

Geron continues rally, up 15%

via: SeekingAlpha at 2018-01-30 12:38:18:000

Micro cap Geron ( GERN +14.5% ) is up again today on a 5x surge in volume. Shares have rallied ~ 35% in two days. More news on: Geron Corporation, Healthcare stocks news, Stocks on the move, Read more … read more...

Little Geron May Soon Be Nipping At The Heels Of Celgene And Incyte

via: SeekingAlpha at 2018-01-29 11:06:17:000

Source: Wikipedia Commons Investment Thesis While biotech giant Celgene ( CELG ) seems to be making all the headlines lately with two multi-billion-dollar acquisitions, little biotech Geron ( GERN ) may very well be the David to Celgene's Goliath. Geron's Imetelstat appears to … read more...

Little Geron May Soon Be Nipping At The Heels Of Celgene And Incyte

via: SeekingAlpha at 2018-01-29 11:06:17:000

Source: Wikipedia Commons Investment Thesis While biotech giant Celgene ( CELG ) seems to be making all the headlines lately with two multi-billion-dollar acquisitions, little biotech Geron ( GERN ) may very well be the David to Celgene's Goliath. Geron's Imetelstat appears to … read more...

Little Geron May Soon Be Nipping At The Heels Of Celgene And Incyte

via: SeekingAlpha at 2018-01-29 11:06:17:000

Source: Wikipedia Commons Investment Thesis While biotech giant Celgene ( CELG ) seems to be making all the headlines lately with two multi-billion-dollar acquisitions, little biotech Geron ( GERN ) may very well be the David to Celgene's Goliath. Geron's Imetelstat appears to … read more...

The Toxicity Of Geron's Imetelstat May Lead To Accelerated FDA Approval

via: SeekingAlpha at 2018-01-12 11:41:37:000

With a market capitalization of just $304MM and a collaboration agreement with Johnson & Johnson ( JNJ ) that may eventually yield milestone and royalty payments in the billions, Geron ( GERN ) may be one of the best opportunities of any publicly traded company for investors today. Drama… read more...

3 Biotechs For The January Effect

via: SeekingAlpha at 2018-01-03 10:58:25:000

Microcaps and Biotechs may be the perfect formula for portfolio jet fuel in early 2018 If you want to increase your odds of finding alpha in your portfolio performance, you need to look beyond indexing and diversified large caps ( SPY ) ( VOO ) to find special situations where potential rewa… read more...

Geron Corporation's (GERN) Post ASH Investor & Analyst Event Conference (Transcript)

via: SeekingAlpha at 2017-12-20 13:54:03:000

Geron Corporation (GERN) Post ASH Investor & Analyst Event Conference December 19, 2017 08:00 AM ET Executives Anna Krassowska - Head of IR John Scarlett - President and CEO Azra Raza - Professor of Medicine and Director of Myelodysplastic Syndromes Center at New York-Presbyt… read more...

Geron (GERN) Post ASH Investor & Analyst Event - Slideshow

via: SeekingAlpha at 2017-12-19 14:37:18:000

The following slide deck was published by Geron Corporation in conjunction with this Read more … read more...

What Geron Investors Really Want To Learn From The Upcoming Conference Call

via: SeekingAlpha at 2017-12-19 04:21:45:000

The upcoming conference call on December 19th is a pivotal event The market has yet to recognize the potential of Geron's ( GERN ) lead drug candidate Imetelstat. Trading at less than 3X cash, Geron stock price is poised to get a boost from the call highlighting recent readouts of Part 1 of … read more...

Your Daily Pharma Scoop: Geron Update, Acorda Resubmits NDA, Sage Rallies

via: SeekingAlpha at 2017-12-08 02:41:11:000

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one day ea… read more...

Geron: It's Breakout Time

via: SeekingAlpha at 2017-12-06 13:46:29:000

The potential market size for Geron's (GERN) Imetelstat is significant With a potential market size potentially exceeding $15 Billion, Geron's late-stage drug Imetelstat has first-tier blockbuster potential. Imetelstat is licensed to Janssen, the pharmaceutical division of Johnson and Johnso… read more...

Geron - Survival Mode

via: SeekingAlpha at 2017-12-04 16:52:40:000

Can Geron hold the dogs of cash starvation at bay until Janssen rings the continuation decision bell; or if Janssen bolts, what then? The thesis of this article is it can, and it will hold them at bay. As for what then, it may not be pretty, but Geron is a survivor. Geron has plan A, plan B … read more...

Geron (GERN) Presents At PiperJaffray 29th Annual Healthcare Conference - Slideshow

via: SeekingAlpha at 2017-11-29 13:42:40:000

The following slide deck was published by Geron Corporation in conjunction with this Read more … read more...

Your Daily Pharma Scoop: Geron's Fate, Celldex Commences Mid-Stage Study, Novartis's Tasigna

via: SeekingAlpha at 2017-11-20 10:51:54:000

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Geron Today we will discuss an articl… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX